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With an extremely poor patient prognosis glioblastoma multiforme (GBM) is one 
of the most aggressive forms of brain tumor with a median patient survival of less than 15 
months. While new diagnostic and therapeutic approaches continue to emerge, the 
progress to reduce the mortality associated with the disease is insufficient. Thus, 
developing new methods having the potential to overcome problems that limit effective 
imaging and therapeutic efficacy in GBM is still a critical need. The overall goal of this 
research was therefore to develop targeted glioblastoma theranostics capable of imaging 
disease progression and simultaneously killing cancer cells. To achieve this, the state of 
the art of liposome based cancer theranostics are reviewed in detail and potential 
glioblastoma biomarkers for theranostic delivery are identified by querying different 
databases and by reviewing the literature. Then tumor targeting liposomes loaded with 
Gd3N@C80 and doxorubicin (DXR) are developed and tested in vitro. Finally, the 
stability of these formulations in different physiological salt solutions is evaluated using 
computational techniques including area per lipid, lipid interdigitaion, carbon-deuterium 
order parameter, radial distribution of ions as well as steered molecular dynamic 
simulations. In conclusion the experimental and computational studies of this dissertation 
demonstrated that DXR and Gd3N@C80-OH loaded and lactoferrin & transferrin dual-
tagged, PEGylated liposomes might be potential drug and imaging agent delivery systems 
for GBM treatment. 
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CHAPTER I 
 
INTRODUCTION 
 
 
I.1 Significance  
In the United States, nearly 80,000 new primary central nervous system (CNS) 
tumors are diagnosed each year with one-half being malignant [1, 2]. The majority of 
diagnosed malignant brain tumors are gliomas with glioblastoma being the most common 
and aggressive form. Due to the high frequency of glioblastoma, finding new therapeutics 
and diagnostics for gliomas is a priority and improvements in drug development and 
measurement of tumor response to therapy may allow advancement of these efforts for 
other types of brain tumors [3]. The current standard of care for newly diagnosed 
glioblastoma patients involves maximum safe surgical resection, followed by 
radiotherapy plus concomitant and adjuvant temozolomide [4]. Given the difficulties with 
identifying precise tumor borders for resection and few therapeutic options, a joint 
meeting was held in 2014 among the Food and Drug Administration (FDA), National 
Cancer Institute (NCI), clinical scientists, imaging experts, clinical trials cooperative 
groups, representatives from pharmaceutical and biotechnology companies, and patient 
advocate groups to discuss new avenues for research in glioblastoma [summarized in 
[3]]. It was concluded that there is a “need to optimize the use of imaging as a surrogate 
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tool to better understand the response to novel therapeutics and the development of a set 
of priorities and action standardization of the MRI protocol for multicenter studies”. 
Thus, there is a significant need in improving the ability to assess the impact of therapies 
in neuro-oncology.  
Contrast agents for magnetic resonance imaging (MRI) containing para-magnetic 
ions such as gadolinium (Gd) are often used to improve the contrast between tissues, 
thereby providing a more accurate diagnosis of a desirable region [5]. Several contrast 
agents (Magnevist®, Gadovist®, Omniscan®) are currently used which cannot easily 
penetrate an intact blood–brain barrier (BBB) unless it is disrupted [6, 7]. In addition, 
these contrast agents are rapidly eliminated from the blood pool due to their low 
molecular weight. Moreover, they can extravasate from the vasculature into surrounding 
tissues accumulation in a tumor due to the enhanced permeability and retention (EPR) 
effect [8] several strategies have been employed to increase specificity and retention time 
[8] but still the complete cure of gliomas is extremely challenging. Further, combining 
the ability to detect glioma borders with the ability to kill the cancer cells in one image-
guided theranostic has been an emerging, leading to poor contrast of a tumor compared 
with healthy tissues. To increase circulation time of contrast agents and their focus of 
research [9-11].  
I.2 Innovation 
Approximately 150 drugs are in development for cancer treatment based on 
nanotechnology [12]. The potentials of nano-formulations include drug solubility, 
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extended retention time and stability in the body, selective targeting, and reduced side 
effects while delivering treatments that are more potent [13]. Another advantage is the 
facilitation of drug delivery across biological barriers, such as BBB which limits access 
to brain tumors [14]. Additionally, nano-based formulations can also facilitate a 
combination of diagnostics with therapeutics (theranostics) for cancer [14]. 
Recent scientific reports underlined that lactoferrin (Lf) protein aids transcytosis 
across the BBB [15] and transferrin receptor (TfR) to be expressed on glioma cells and 
glioma stem cells [16]. On the other hand unlike other contrast agents such as Gd-DTPA 
[17], the fullerene cage in Gd3N@C80 is extraordinarily stable species which avoids a free 
Gd release. In addition, Gd3N@C80 has 25-fold more relaxivity compared to traditional 
Gd contrast agents due to the 3 Gd atoms inside the fullerene cage [18] and no overt 
toxicological endpoints have been observed in several studies with the Gd3N@C80 [18, 
19].  
Therefore, the innovative formulations herein are < 100 nm, PEGylated, Tf & Lf 
tagged (dual targeting), doxorubicin (DXR) and Gd3N@C80 loaded theranostics. The 
theranostics are characterized and their effectiveness is tested in-vitro on U251-MG cells. 
Furthermore, the stability and dynamics of Gd3N@C80 containing lipid bilayers in 
physiological salts solutions and at human body temperature are evaluated using 
molecular dynamic simulations. 
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I.3 Approach  
The overall goal of this dissertation is to develop a glioblastoma nanotheranostic 
having enhanced tumor targeting, imaging, and cancer killing capabilities. To this end 
liposomal cancer theranostics are reviewed and possible targets are identified. Then dual 
and single targeted theranostics are developed and their cellular uptake by glioblastoma 
cells examined in vitro. Finally, the stability of these theranostics is evaluated by 
studying the structural stability of C80 or C80(OH)42 loaded lipid bilayers solvated in 
physiological salt solutions by using NAMD molecular dynamics simulations.  The 
specific aims, the rationales and the strategies to realize the overall goal are explained 
below: 
I.3.1 AIM 1: Review cancer theranostic liposomes and explore potential 
glioblastoma biomarkers  
Rationale: To develop a new effective theranostic liposome, it is necessary to 
assess the state of the art of liposome based cancer theranostics and study the limitations 
of existing formulations. Furthermore, receptors useful for the transcytosis process across 
the BBB and potential glioblastoma biomarkers should be explored. 
Strategy: liposomes based cancer theranostics are categorically reviewed with 
more emphasis on the formulation mechanisms, single/dual targeted and non-targeted 
theranostic liposomes and their application in cancer treatments. Potential glioblastoma 
biomarkers are identified through literature review and by enquiring different databases 
that are freely available for public use.  
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I.3.2 AIM 2: Synthesize, characterize and test glioblastoma-targeting theranostics 
Rationale: While IL-13 receptors appear to be uniquely upregulated to high levels 
of glioblastoma cells there is concern about non-glioblastoma cell binding of IL-13 
receptors (e.g. immune cells). Therefore, it is necessary to develop and test new 
dual/single ligand theranostic liposomes while keeping the diagnostic (Gd3N@C80) and 
therapeutic (DXR) components the same.  
Strategy: Although several potential targets have been identified through the 
strategy mentioned in aim 1, it was necessary to test those with promising results in 
clinical trials. Phase I and Phase II clinical trial results demonstrated that the transferrin 
receptor as a viable target for tumor reductions in patients with glioblastoma [20, 21]. 
Lactoferrin was also reported to be a viable ligand to cross the BBB. Hence these two 
targets, transferrin & lactoferrin, were considered for the dual targeting process. 
Theranostic development: Functionalized and non-functionalized Gd3N@C80 
containing PEGylated liposomes are developed by a thin lipid film hydration process. 
DXR was remotely loaded into the liposomes using a PH gradient. The liposomes were 
tagged with transferrin and lactoferrin using amine-amine or amine-carboxylic 
conjugation processes. Encapsulation efficiencies are computed using standard curves 
and the particles are characterized using zetasizer, nanosight, Fourier-transform Infrared 
Spectroscopy (FTIR) and Ultraviolet-Visible Spectrophotometry (UV-VIS) analysis.  
Theranostic testing: The ability of each theranostic to bind or endocytosed, and 
kill glioma tumor cells must be demonstrated in vitro. The hypothesis is that the 
theranostics modified with transferrin & lactoferrin will have better BBB crossing 
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capability, be up taken by glioblastoma cells, and kill glioma tumor cells. To this end the 
expressions of targets were assessed using western blotting and PCR. To compare the 
cytotoxic effect of these dual and single targeted theranostics, a microscopic examination 
of U251-Mg cells was carried out after the cells are treated for 24 & 72 hours. The 
enhanced cytotoxic effect of these theranostics was further confirmed by MTT assay. 
I.3.3 AIM 3: Study the stability of these theranostics using molecular dynamic 
simulations 
Rationale: The stability of Gd3N@C80 containing liposomes and the interaction of 
the fullerene cages with the lipid bilayer components must be evaluated in different 
physiological salt solutions and at human body temperature. The hypothesis is that; OH-
functionalized or non- functionalized Gd3N@C80 will never affect the structural stability 
of the lipid bilayer compartment of those liposomes in physiological salt solutions. 
Strategy: A complete structural stability study using experiments requires several 
equipment and expensive chemicals. Therefore, the strategy was to study structural 
properties using molecular dynamics simulations and compare the results with 
experimental reports in the literature. As Gd3N in Gd3N@C80 is firmly confined within 
the fullerene cage, the molecular dynamics simulations focus on the external 
compartments (C80 and C80(OH)42). To this end the structural variations of C80 or 
C80(OH)42 (C80/C80(OH)42) loaded versus C80/C80(OH)42 free lipid bilayers immersed in 
different physiological salt solutions are evaluated. The dynamics of functionalized and 
non-functionalized fullerenes across the lipid bilayers are also evaluated using steered 
 
7 
 
molecular dynamic simulations. And the results are discussed in terms of the stability of 
the molecules inside the lipid bilayers and in terms of the interactions of the molecules 
with the lipid bilayers. 
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CHAPTER II 
 
UPDATE ON LIPOSOME-BASED CANCER THERANOSTIC AND       
GLIOBLASTOMA BIOMARKERS 
 
 
II.1 Abstract 
Glioblastoma is the deadliest brain tumor where the average survival of a newly 
diagnosed case is less than 15 months. While new diagnostic and therapeutic approaches 
continue to emerge there has still been little progress in reducing the mortality associated 
with the disease. Liposome-based theranostics, which combine diagnostic and therapeutic 
capabilities, are one strategy being investigated for glioblastoma treatment. Here, current 
theranostic liposomes for cancer treatments are reviewed along with challenges 
associated with their development and use. This review highlights potential biomarkers, 
mined from different databases, as targets for optimum glioblastoma theranostic delivery. 
These biomarkers can be targeted to improve the delivery of imaging agents and 
cytotoxic or cytostatic drugs through ligand-receptor mediated endocytosis, antibody 
(fragment) based delivery, peptide based delivery, or other mechanisms such as a 
recombinant immunotherapy modality.  
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II.2 Introduction  
The integration of diagnosis and therapy into a single nanoparticle has led to the 
birth of a field named ‘nanotheranostics’ which has given hope to developing innovative 
research to diagnose, treat, and follow up patients with various forms of cancer [22]. The 
rationale for using nano-size based molecules for developing nanotheranostics includes 
their small size to potentially overcome challenges with crossing the BBB, ability to be 
targeted to cancer-specific biomarkers, and the proven multimodal capabilities of 
designing nano-sized structures which serve different functions. However, it is still 
challenging to incorporate multiple components, having different purposes, on a single 
nano scale theranostic that is entirely adequate for combined diagnostics and therapy. 
Several noninvasive imaging methods are currently being used for glioblastoma 
diagnostics. These include magnetic resonance (MR), computed tomography (CT), 
ultrasonic (US) and positron emission tomography (PET) imaging techniques. These can 
simultaneously be integrated with therapeutic strategies, such as chemotherapy, gene 
therapy, photodynamic therapy (PDT), and photo thermal therapy (PTT) to monitor the 
bio distribution, drug release kinetics and therapeutic efficacy [23]. Nanomaterials are an 
attractive platform for developing such theranostics [24, 25].  
Liposome can be an important component of theranostics. There have been 
growing numbers of trials and approvals of liposome-based delivery systems. Several 
liposome-based therapeutics and diagnostics, including those approved by the FDA, are 
now used in the clinic, in clinical trials, or in pre-clinical developments [26-28]. The most 
 
10 
 
recently approved liposomal drug carrier Onivyde® (liposomal irinotecan), a 
topoisomerase I inhibitor is used as a second line treatment for metastatic pancreatic 
cancer [27]. Nevertheless, there is no FDA approved theranostic liposome, and there is no 
FDA approved targeted liposome for glioblastoma treatment. Given the wide acceptance, 
safety, and effectiveness of liposomes as a platform for developing new diagnostics, 
therapeutic, and nanotheranostics, all the efforts to develop new nanotheranostics using 
liposomes are discussed, in this chapter, with a focus on specific glioblastoma targets. 
II.3 The Potential of Theranostic Liposomes and Formulation Strategies  
The advantage of liposome-based nanotheranostics is twofold. First combining 
multiple imaging modalities and therapeutic functions in one complex is possible by 
exploiting the inner core, the double layer or by attaching imaging or therapeutic agents 
from outside after functionalizing the phospholipids. Second, liposomes are flexible, 
biocompatible, biodegradable and are suitable for conjugation with ligands or antibodies 
[29]. Liposomes can also easily fuse with target cancer cells on the surface, which 
facilitates the transport of drugs across biomembranes.  
The formulation of liposomes for drug delivery was started with non-targeted 
liposomes in the 1960s [30-32] and has evolved over time to those incorporating 
nanoparticle, PEGylating and targeting moieties [31, 33]. Liposomes are also being 
designed to release their payload as a result of external stimuli such as heat [34], light 
[35], magnet [36], ultrasound or internal stimuli including enzymes, redox or PH 
sensitive [37]. Liposomes are exploited for cancer drug delivery, reaching up to phase IV 
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in a clinical trial (example LIPUSU® for Metastatic breast cancer) and some are already 
FDA approved for cancer treatment (example MyocetTM also for Metastatic breast 
cancer) [38]. DOXIL® was clinically approved for the treatment of Kaposi’s sarcoma 
and ovarian breast cancers and recently Marqibo® was approved for Lymphoblastic 
leukemia [31, 32]. Hence the following sections focus on theranostic liposomes, in cancer 
studies, utilizing quantum dots (QDs), metals, and radionuclides.  
II.3.1 QDs-encapsulated theranostic liposomes 
Many studies have attempted to develop QD-based theranostic liposomes for 
cancer treatment by integrating the fluorescence properties of QD with therapeutic drugs 
(Table 1). QDs together with magnetic, paramagnetic or radioactive particles were 
engineered for more sensitive and quantitative diagnostic applications [22]. Liposome-
QD hybrid vehicles were also developed by incorporating trioctylphosphine oxide 
(TOPO) capped, CdSe/ZnS QD into the lipid bilayers containing DSPC, cholesterol, and 
DSPE-PEG2000 followed by loading anticancer drug DXR into the aqueous core, 
remotely, by a PH gradient [39]. 
Novel drug delivery monitoring systems can also be designed using QDs by 
associating the fluorescence intensity of the QDs to drug concentration [40]. Liposomal 
formulations having QD in the lipid bilayer and camptothecin (CPT) or irinotecan inside 
the core compartment of cationic lipids were reported to indicate improved florescence, 
cytotoxicity and migration inhibition role in melanoma cells [41]. The intensity of 
fluorescence or localization of QDs inside cell compartments can be maximized by 
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loading QD-drug conjugates inside targeted liposomes. For example, D-alpha-tocopherol 
polyethylene glycol 1000 succinate mono-ester coated theranostic liposome containing 
docetaxel and QDs was developed for breast cancer [42]. In those formulations folate 
receptor targeted liposomes showed significantly higher cellular uptake compared to non-
targeted liposomes [42].  
More recently, a tumor-targeted lipid nanocarrier for gene delivery and tumor bio-
imaging using QD was developed by coupling an aptamer to the epidermal growth factor 
(EGF) receptor and was found to be effective tumor targeting [43]. QDs and Topotecan 
(TOPO) containing liposomes were formulated using a thin lipid film hydration followed 
by a pH-gradient based drug loading process. In these formulations, liposomal TOPO 
showed significantly higher cellular uptake and cytotoxicity compared to free TOPO 
when tested in HeLa and A549 cells [44]. Other theranostic liposomes incorporating QDs 
and apomorphine reported in [45] avoided liver uptake and enhanced brain targeting as 
confirmed by a hyperspectral analysis of QDs localization [45].  
II.3.2 Gadolinium (Gd)-encapsulated theranostic liposomes 
Approximately 40% of magnetic resonance imaging (MRI) examined cancer 
patients receive Gd-based contrast agents which has proven to improve cancer detection 
and diagnosis [46-48]. One of the limitations of using free Gd as a contrast agent is the 
possibility of developing nephrogenic systemic fibrosis (NSF), especially in renal 
impaired patients resulting from free Gd deposition in tissues [48]. Nonetheless, several 
theranostics have been reported in the literatures that incorporate Gd as the imaging 
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component (Table 1). The αvβ3 integrin targeting peptide c(RGDyk) has been used to tag 
Gd-DOTA and paclitaxel (PTX)-containing liposomes for drug delivery to A549 tumor 
cells and shown a 16-fold increase in T1 relaxivity compared to non-targeted groups [49]. 
Similarly, neural cell adhesion molecule-targeted binding peptide coated liposomes 
loaded with both DXR and a lipophilic Gd derivative were generated that induced an 
enhanced in vitro DXR internalization within Kaposi's cells compared to untargeted 
liposomes [50]. These targeted, Gd-labeled liposomes allowed the concomitant MRI 
visualization of the drug delivery in the tumor region [50]. Another which integrates 
mesoporous silica nanoparticle (MSNs) with Gd and tagged with a pro-apoptotic peptide 
KLA provided better biocompatibility, exhibited cellular uptake, and induces 
mitochondrial swelling and apoptosis in MCF-7 cells [51]. A theranostic liposome which 
integrates magnetic resonance (MR), near-infrared (NIR) fluorescence, nuclear imaging 
and DXR was reported in [52]. These liposomes were first formulated by incorporating 
DSPC, cholesterol, Gd-DOTADSPE, DOTA-DSP and by hydrating with ammonium 
sulfate solution. Then a lipidized NIR fluorescent detector, IRDye-DSPE, was post-
inserted into the pre-manufactured liposomes. Finally, DXR was loaded remotely and the 
resulting liposomal formulation was radiolabeled with 99m Tc or 64Cu for single photon 
emission computed tomography (SPECT) or positron emission tomography imaging 
respectively (PET) [52]. Intratumoral injection of these theranostics in rats with 
squamous cell carcinoma of head and neck tumor xenografts, and subsequent imaging 
using MR, NIR, SPECT and PET displayed a promising result. 
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Attempts to minimize issues associated with free Gd toxicity, one strategy was to 
incorporate the Gd within carbon spheres such as Gd3N@C80 [18]. A glioblastoma-
targeting theranostic (GTTN) liposome containing DXR and Gd3N@C80 targeted with IL-
13 induced cell death in IL-13 receptor expressing U-87 cells in vitro, and shrink human 
brain tumors transplanted in mice compared to non-targeted [53].  
Another strategy uses temperature or ultrasonic change within the tumor to utilize 
the therapeutic and diagnostic components of a theranostic. A thermosensitive liposome 
demonstrated enhanced DXR release and contrast upon heating to 40-42 °C and the 
process completely regressed EMT-6 tumor model in mice [54]. Similarly, a theranostic 
liposome developed using temperature sensitive copolymer, a dendron lipid attached to a 
Gd-chelate and DXR suppressed tumor growth after intravenous injection in tumor 
bearing mice [55]. Liposome drug release can also be controlled by ultrasound. For 
example, ultrasound-triggered release of DXR in Gd-containing liposomes was reported 
to increase drug accumulation in the intratumor environment, enhanced TI contrast, and 
caused a complete regression of adenocarcinoma [56]. Another generates MRI contrast 
when the liposomes are triggered by local exposure to ultrasound with concomitant 
release of DXR [57].  
To sum up, there is a tremendous progress in the development of Gd containing 
theranostic liposomes and these efforts have promising future for cancer treatments. 
However, the contrast agents must be loaded inside stable and targeted liposome 
structures or has to be loaded into targeted liposomes in the form of stable Gd-chelates to 
avoid possible Gd dissociation.  
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II.3.3 Iron oxide-encapsulated theranostic liposomes 
Superparamagnetic iron oxide nanoparticles (SPIONs) based T2 MRI contrast 
agents may be another alternative for patients at risk for Gd-induced NSF [58, 59]. A 
hybrid liposome containing amphiphilic hyaluronic acid hexadecylamine polymer (HA-
C16) as a targeting ligand, dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 
cholesterol, SPION, and docetaxel (DTX), was examined for delivery to human breast 
cancer cells overexpressing CD44 receptors (Table 1) [60]. In this formulation, citric 
acid-coated SPIONs were embedded in the aqueous cores while DTX was encapsulated 
in the hydrophobic bilayer. Confocal as well as flow cytometry experiments indicated 
superior cellular uptake of HA-C16 tagged liposomes compared to non-targeting 
liposomes [60]. Similarly, liposomes loaded with a Gonadorelin-functionalized SPION 
and mitoxantrone (MXT) showed a significantly increased uptake by MCF-7 breast 
cancer cells overexpressing the luteinizing hormone releasing hormone (LHRH) receptor 
compared to the uptake of non-targeted liposomes [61]. A liposome-type formulation 
comprising iron oxide core, DXR containing polymer (dextran) coated with acetylated 
lipids and PEG demonstrated deep imaging capability [62]. Therefore, combining 
SPIONs with therapeutic drugs may overcome the limitations observed in Gd-based 
constructs when administered to glioma patients with a previous NSF history. 
II.3.4 Radionuclide-liposome theranostics  
Radiolabeled liposome theranostics are also being used for disease diagnosis and 
treatment of cancers [63, 64]. Rhenium (186Re) is an attractive radionuclide for imaging 
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and tumor therapy due to its 3.78 days half-life, with 137 keV gamma emission for 
scintigraphic imaging and 1.07 MeV β emission with a tissue penetration depth range of 
2-4 mm [65]. DXR containing liposome labelled with 186Re for use in SPECT based 
imaging and chemotherapy demonstrated good bioavailability, tumor targeting and 
localization in a head and neck cancer xenograft model in rats [65]. A similar construct 
radiolabeled with Technetium (99mTc) was used to monitor the localization of liposomal 
drug in rats [66]. Other radionuclides such as Iodine 123I/131I have been employed for 
diagnosis and radionuclide based therapy of thyroid cancers [67]. Some of the challenges 
in using radionuclides for therapy is their short half-life, limited depth of penetration, and 
lower decay energy of the nuclides in a biological system. Conversely, if the energy of 
the emitted radiation is very high, it may cause a damaging effect on surrounding normal 
cells. Therefore, it is necessary to determine an optimum energy range radionuclide when 
developing theranostic liposomes with radionuclides.  
II.3.5 Other metals-encapsulated theranostic liposomes 
Other metals used as imaging agents include gold, silver and manganese which 
can be enclosed in the aqueous compartment, loaded in the liposome lipid bilayer or 
attached to the outer part of the liposomes (Table 1). Recently a bubble-generating 
nanoparticle incorporating ammonium bicarbonate and gold nano-rods in folic acid-
conjugated liposomes was designed and proven to be effective for a multimodal imaging 
and DXR release using a hyperthermia when tested in S180 tumor-bearing mice [68]. 
Similarly, a thermosensitive hybrid system incorporating gold, silver, and iron oxide 
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nanoparticles in the lipid bilayers loaded with DXR was reported in [69] and 
demonstrated an improved DXR release due to external heating. Furthermore a low 
temperature-sensitive liposomal theranostic incorporating MnSO4 and DXR was 
formulated and tested for drug release efficiency on rat fibrosarcoma tumor cells using 
MRI [70]. Interestingly, the relaxivity of the Mn2+ inside the temperature sensitive 
liposomes was above free Mn2+ hypothesized to be due to a partial binding of Mn2+ with 
the phospholipid head groups which increases its interaction with water by reducing the 
Brownian motion of free Mn2+ [70].  
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Table 1. Summary of Liposome-based Cancer Theranostics Categorized with Imaging Agents. Most lipid abbreviations 
accord the nomenclature in [71], otherwise explained in the references provided 
. 
Imaging agent Drug Disease  
(cell line) 
Lipid composition target  
(ligand) 
Referen
ce 
QD CPT Melanoma SPC, Chol, DSPE-PEG  [41] 
QD DTX MCF-7 DPPC, Chol, TPGS, DSPE-
mPEG-FA 
Folic acid [42] 
QD TOPO Hela, A549 DSPC, Chol  [44] 
QD Apomorphine bEND3 PC, Chol, SA, DSPE-MPEG  [45] 
QD SiRNA MDA-MB-231 DMKE, Chol, DSPEM-
PEG2000 
Anti EGFR aptamer [43] 
Gd3N@C80 DXR GBM DPPtdCho, Chol, DSPE-PEG IL-13, IL13R2 [53] 
Gd-DOTA Paclitaxel A549 DSPC, DSPG, MPEG-2000-
DSPE 
Peptide (αVβ3 targeting) [49] 
Gd-DOTA DXR Head and neck DSPC, DSPE, Chol  [52] 
Gd-DTPA DXR EMT-6 cells DPPC/Brij78  [54] 
GdDOTAMA(C18)
 
DXR TS/A DPPC/DSPC/Chol/DSPE-
 
 [56] 
Gd-
DOTAMA(C18)2 
DXR Kaposi's cells POPC/DSPE-PEG-PDP/DSPE-
PEG 
NCAM-targeting 
Peptide  
[50] 
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GD-DOTA DXR Colon carcinoma 
26 
EGGPC, Chol, PEG-PE  [55] 
Gadoteridol 
[Gd(HPDO3A) 
(H2O)] 
DXR Breast-TS/A DPPC/DSPC/Chol/DSPE-
PEG2000 
 [57] 
Gd (MSNs) KLA peptide MCF-7 DPPC, DSPE-PEG2000, Chol  [51] 
SPIONs DTX Breast DPPC, Chol HA-C16 [60] 
SPIONs MXT Breast HSPC, Chol, and PEG2000-
 
Gonadorelin(peptide) [61] 
SPIONs DXR Lung/pancreatic DOPE, DSPC-PEG2000, Chol, 
 
 [62] 
99mTc DXR  Lipids used to formulate 
DOXIL® 
 [66] 
136Re 
Radionuclide 
DXR  Lipids used to formulate 
DOXIL® 
 [65] 
Indocyanine green 
(Photoacustic) 
DXR Breast HSPC, DSPE-PEG2000, Chol MUC-1 [72] 
Gold DXR MCF-7 Lecithin, Chol, DSPE-PEG2000 Folic acid [68] 
Gold, silver, 
SPIONs 
 
DXR  DPPC, MSPC, DSPE-PEG2000  [69] 
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II.4 Glioblastoma Targets 
Several stategies to overcome the BBB are reported in the litrature among which 
receptor mediated delivery is a matured and better option [73, 74]. Several glioblastoma-
specific targets are also reported [75-78] ( Table 2). However, it is critically important 
that any moiety targeted on cancer cells does not result in activation of the cells. Here, a 
synopsis of glioblastoima targets are provided that could be examined in the context of 
their potential in developing glioblastoma-specific theranostics.  
  
Table 2. List of Receptors that are often used for Targeted Drug Delivery in Glioblastoma 
Treatments 
 
Receptor Role in glioblastoma Related 
referenc
es 
Ephrin type-A receptor 2 (EphA2) Proliferation [79, 80] 
Urokinase plasminogen activator receptor  
             (uPAR) 
Proliferation/activation [81, 82] 
Transferrin receptor (TfR)  [83] 
Epidermal growth factor receptor  
             (EGFR/ERBB1) 
Proliferation [84, 85] 
Epidermal growth factor receptor  
        variant III (EGFRVIII) 
Proliferation/angiogenesis [86, 87] 
Interleukin receptor 4 (IL-4Ra)  [88] 
Interleukin receptor 13 (IL-13Ra2)  [89] 
Fibroblast growth factor-inducible 14 
          (Fn14) receptor 
 [90, 91] 
Vascular endothelial growth factor 2  
               (VEGFR2) 
Proliferation/angiogenesis [85, 92] 
Receptor tyrosine kinase 2 (Erb-b2/HER2)  [93] 
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Anaplastic lymphoma receptor tyrosine 
       kinase (ALK) 
 [94] 
Transforming growth factor,  
       beta receptor II (TGFBR2) 
 [95] 
C-X-C motif chemokine receptor 4 (CXCR4)  [96] 
Met proto-oncogene (MET) Proliferation [97, 98] 
MER proto-oncogene, tyrosine kinase (MerTK)  [99] 
 
 
II.4.1 Determination of potential glioblastoma targets  
The overall strategy for exploring new potential glioma targets is depicted in 
(Figure 1). Receptor genes common in the Human Protein Atlas version 16.1, Ensemble 
83.38 (focusing on glioma) [100-102] and receptor-ligand binding information from 
UCLA database of interacting proteins [103] were mined using Visual Basic Application 
code. The glioma data from the Human Protein Atlas incorporates immunohistochemistry 
data from tissue microarrays of glioma tumor patients to provide expression scores based 
on: 1) staining intensity (negative, weak, moderate or strong) and 2) fraction of stained 
cells (rare, <25%, 25-75% or >75%) scored as “not detected”, “low”, “medium” and 
“high” [104]. Such expression level data integrated with protein-ligand interaction data 
provide valuable information on receptor’s role in cancer cell migration or invasion. 
Common receptors/genes with “high” and a “medium” scores were further evaluated for 
their expression level on different glioblastoma classes by querying open access 
databases such as the Repository for Molecular Brain Neoplasia Data (REMBERANDT) 
[105] and The Cancer Genome Atlas (TCGA [106]). 
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Figure 1. Potential Biomarkers (targets) Data Mining Strategy from Freely Available Databases Open for Public use. Receptor 
proteins/genes overly expressed in glioblastoma patients available in the protein atlas and database of interacting proteins [104] 
were selected by filtering common receptors, expression level, and by comparing these data with expression of the same 
receptors in normal glial cells. The expression of resulting receptors were further analyzed with respect to glioblastoma 
subtypes by querying the REMBRANDT and TCGA glioma data through project Betastasis [106]. As relying on databases 
alone may not be sufficient, literature was consulted to study the role of the receptors in glioma migration, proliferation, 
differentiation etc.  
The protein atlas 
Pathological data 
(Glioma) 
Database of 
interacting 
proteins 
(Protein-ligand 
interaction) 
REMBERANDT 
(Glioma database) 
TCGA 
(Glioma database) 
Literature review 
Step-1 
• Identifying common receptors/genes in both databases 
• Ranking receptors/genes according to expression level 
in glioma 
• Evaluating the expression level of identified 
receptors/genes in normal glial cells 
Step-2 
• Comparing receptor’s expression on glioma subclasses by 
mining REMBERANDT (i.e. expression on glioblastoma, 
oligodenrogliomas and astrocytoma) 
• Comparing receptor expression on glioblastoma subclasses by 
mining TCGA (i.e. expression level in classical, 
mesenchymal, proneural and neural) 
Step-3 
• Reviewing the role of each receptor in glioma 
proliferation, activation, differentiation  
• Reviewing if a given receptor was used for targeted drug 
delivery, mainly, in gliomas 
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II.4.2 Receptor expression and their role in glioma 
Following the data mining strategy explained in section 3.1, the total number of 
patients positive for a specific receptor (i.e. including less, moderate or higher expression 
levels) and those moderately and highly expressed (excluding those with lower 
expression) are indicated in Figure 2. The expression levels of those receptors in 
glioblastoma subclasses and normal glial cells was further assessed and presented in 
Table 3. As an example, protein tyrosine phosphatase, receptor-type, Z polypeptide 1 
(PTPRZ1) is highly expressed in glioblastoma, oligodenderoglioma and astrocytoma 
[104]. Further, it is expressed in all classes of glioblastoma with more on classical and 
proneural subclasses (Table 3). Inhibiting PTPRZ inhibits glioblastoma cell proliferation 
and migration [107] and decreased the sphere forming abilities of C6 and U251-MG 
cancer cell lines [107] making it a potential target for theranostic delivery.  
The protein tyrosine phosphatase receptor type B (PTPRB; Figure 2) is also 
highly expressed in glioblastoma but its role in cell inhibition or activation is not clear. 
While mutations in PTPRB increased angiogenesis in angiosarcoma [108], normal 
PTPRB overexpression didn’t lead tumor aggression rather inhibits VEGFR2, VE-
cadherin, and angiopoietin signalling, reduces cell proliferation and has general anti-
cancer cell properties [108, 109]. Other studies suggest the receptor’s interaction with its 
ligand pleiotrophin (PTN) may induce glioma migration [110]. The neurotrophic tyrosine 
kinase receptor type 2 (NTRK2) is highly expressed on gliomas making it a novel 
biomarker for glioma targeting [111, 112]. Further, chemokine receptor 2 (CCR2) is also 
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highly expressed on glioblastoma cells compared to normal glial cells [113]. CCR2 is 
involved in chemokine signalling and appears to play a dual role in mediating early tumor 
immunosurveillance and sustaining the growth and progression of established neoplasms 
and has been used as a way to inhibit glioma cell migration [113, 114]. 
Oncostatin M receptor (OSMR) is expressed relatively higher on mesenchymal 
sub-classes of glioblastoma and knocking-down of OSMR suppresses proliferation and 
tumor growth in mouse glioblastoma cells as well as in human brain tumor stem cell-
xenografts in mice [115]. Furthermore, OSM-OSMR mediated signaling via signal 
transducer and activator of transcription 3 (STAT3) drives glioma cells towards a 
mesenchymal type making it an attractive target for glioblastoma targeting [116]. Activin 
A receptor type 1 (ACVR1) is another potential target which is expressed relatively 
higher on mesenchymal subclasses in glioblastoma. It was reported that ACVR1 
mutations and aberrant bone morphogenetic protein (BMP) signaling as a new potential 
therapeutic target in pediatric diffuse glioma [117]. Epidermal growth factor receptor 
(EGFR) highly expressed in GBM is widely used as a target in glioblastoma treatments 
[118]. Platelet-derived growth factors A & B (PDGFRB and PDGFRA) are also potential 
targets for glioma treatments where targeting PDGFRB with a multi kinase inhibitor drug 
(imatinib) caused effective killing of glioma stem cells [119]. PDGFRB silencing also 
increased radio sensitivity of C6 glioma cells [120]. Other GBM targets for inhibition 
include P75 neurotrophin receptor [121], transforming growth factor beta receptor 1 
[122], chemokine receptor 9 [123], tumor necrosis factor receptor superfamily members 
(e.g. TNFRSF11A) [124], bone morphogenetic protein receptor type IA [125], colony 
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stimulating factor 1 receptor [126] and the Leukemia inhibitory factor receptor alpha. 
IL13RA2 receptor is a promising target for glioblastoma treatment for a targeted fusion 
protein ( IL13-PE38QQR; Cintredekin Besudotox), composed of human IL-13 and a 
truncated, mutated version of pseudomonas exotoxin (PE) is in phase III clinical trails 
[127-129]. 
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Table 3. Potential Targets for Theranostic Delivery in Gliomas. The number of patients stained positive with respect to the total 
number of patients (column 2) and expression on normal cerebral cortex (column 3) are from The Protein Atlas and expression 
on glioblastoma subtypes (Column 4) is from TCGA. Expression on glioma subtypes (column 5) is from REMBERANDT. 
Abbreviations are: GBM- glioblastoma, ODGM -oligodendroglioma and ACM - astrocytoma.  
Protein/gene 
[130] 
# of 
patients 
[100] 
Normal 
cerebral 
cortex 
expression 
[100] 
Sub-class 
expression:  
(TCGA)[106] 
N-neural 
C-classical 
M- 
mesenchymal 
P-proneural 
Sub-class expression: 
REMBRANDT[105, 
106] 
 GBM 
 ODGM 
 ACM 
 
Involvement in 
proliferation, 
migration 
[131] 
Cancer/ 
Glioma 
Related 
study 
CCR9 11/11 none N, C, M, P A>C>B 
 
[132, 133] 
TNFRSF11A 11/12 none 
 
A, C, B 
 
[134] 
MET 11/11 none 
 
A, C, B 
 
[85, 97] 
CSF1R 11/12 none M, P, N, C A, C, B 
 
[135, 136] 
PDGFRB 9/11 none M A> C, B proliferation, 
migration 
 
IFNAR1 8/10 none M, N A>B, C 
 
[137] 
NGFR 7/12 none P A>B, C 
 
 
EGFR 7/12 none C A>B, C proliferation  
CCR2 5/12 none   
 
[138] 
INSR 10/12 low 
 
B>C, A 
 
[139] 
TNFRSF1B 9/10 low M, N A>B, C 
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OSMR 8/12 low M, C A>C, B proliferation [140] 
ERBB3 7/11 low   
 
 
ACVR1 6/12 low M, N C>A>B 
 
[141, 142] 
NRP1 6/10 low M, C A>B>C proliferation [143] 
BMPR1B 6/12 low N C>B, A 
 
[144] 
LIFR 12/12 medium-
low 
C C>B, A proliferation  
PTPRZ1 11/11 medium-
low 
C, P, M, N C, A, B 
 
[145, 146] 
IGF2R 10/12 medium-
low 
M, P, C, N A>C>B 
 
 
IL11RA 10/11 medium   proliferation   
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Figure 2. The Expression of Potential Targets in Glioma Patients Extracted using a VBA Code which searches for Commonly 
Expressed Proteins in the Human Pathology Atlas [104] and Database of Interacting Proteins [106]. A) The numbers on the top 
of each bar indicate the number of patients positive for a particlular receptor (includes high, moderate and low expression). B) 
Potential targets that are highly and moderately expressed.   
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II.5  Summary  
To date there is no FDA approved targeted theranostic liposome for glioblastoma 
treatment. Any strategy for identifying suitable targeting ligands for glioblastoma must 
consider relative expression of the target on glioblastoma cells compared to healthy cells, 
whether the receptor/target activates or inhibits cells growth, and the ability to effectively 
develop and incorporate the targeting ligand on the surface of the theranostic. 
Combinatorial targeting of more than one glioblastoma marker such as those outlined in 
(Table 2 & Table 3) may enhance tumor specific killing while reducing unwanted 
binding to healthy cells and/or enhancing the ability of the theranostic to cross the blood-
brain barrier. In addition, the resulting theranostic must be able to cross the blood-brain 
barrier without degradation, specifically target the tumor cells, and remain functional 
after reaching the cell in its ability to enhance imaging for diagnosis while in parallel 
release cancer killing therapeutics.  
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CHAPTER III 
 
DESIGN AND TESTING OF DUAL-TARGETED GD3N@C80 CONTAINING 
GLIOBLASTOMA THERANOSTICS 
 
 
III.1 Abstract 
The majority of the malignant brain tumors are gliomas with glioblastoma being 
the most common and aggressive type. Due to its extreme infiltrative nature and higher 
occurrence frequency, finding new glioblastoma therapeutics and diagnostics is a high 
priority. In line to this several mono-targeting glioblastoma theranostic liposomes are 
reported in the literature. Herein, a dual-targeted theranostic is synthesized on the 
hypothesis that targeting multiple receptors would enhance delivery precision. DXR and 
endo-fullerene (Gd3N@C80) were encapsulated within liposomes and conjugated with 
transferrin (Tf) and lactoferrin (Lf). The hydrodynamic size, zeta potential, encapsulation 
efficiency and tagging with proteins of the Gd3N@C80 and DXR loaded liposomes were 
characterized using dynamic light scattering (DLS), inductively coupled plasma mass 
spectrometer (ICP), Fourier-transform infrared spectroscopy (FTIR), and ultraviolet-
visible spectrophotometry (UV-VIS) analysis. As verification of efficacy, the Tf & Lf  
dual-tagged theranostic liposomes were able to significantly induce cell death  compared 
to Lf mono-tagged theranostics.
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III.2 Introduction 
Close to 80,000 new glioma cell-involved primary central nervous system (CNS) 
tumours are diagnosed each year in the United States with roughly half being malignant 
[1, 2]. The prognosis of patients with malignant gliomas remains extremely poor, with a 
median survival of less than 15 months [147]. Hence, finding new therapeutics and 
diagnostics for gliomas is a high priority and improvements in drug development, and 
measurement of tumor response to therapy may allow advancement of these efforts for 
other types of brain tumors [148]. 
Among all gliomas, GBM, a World Health Organization grade IV glioma, is the 
most common and lethal primary malignancy of the central nervous system [149]. 
Targeted deliveries of therapeutics in GBMs mainly rely on single biomarkers, and the 
chemotherapeutics suffer from lack of specificity causing significant healthy cells death. 
Another major obstacle for any GBM diagnostic or therapy is transporting it across the 
blood brain barrier (BBB).  
Using Lf as a targeting ligand for GBM is attractive as it is able to cross the BBB 
and the transferrin receptor (TfRC) is expressed on glioma cells and glioma stem cells 
[150, 151]. Indeed, Lf has been extensively used for targeted delivery of several drugs to 
the brain [152, 153] and was used for a magnetic resonance imaging (MRI) agent 
delivery to the brain [154]. Furthermore, Phase I and Phase II clinical trial results 
demonstrated that the transferrin receptor as a viable target for tumor reductions in 
patients with GBM [155]. Similarly, Tf is considered a viable ligand for targeted delivery 
in gliomas [156, 157]. 
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Tf as well as Lf are often used separately in crossing the BBB and targeting 
glioma cells [158]. However, it was previously reported that Tf or Lf tagged 
nanoparticles have some limitations. For instance, Tf tagged nanoparticles were reported 
to be deposited in major organs such as heart, kidney, spleen, lung etc.[159]. On the other 
hand, Lf tagged nanoparticles were reported to be identified by macrophages more easily 
compared to Tf tagged nanoparticles [159]. Lf tagged nanoparticles were found to get 
accumulated more in liver compared to Tf attached nanoparticles [159] and there are 
debating reports on the BBB crossing capabilities of Tf-tagged versus Lf tagged 
nanoparticles [159, 160]. These debates could be due to differences on the expression 
level of TfR & LfR on the BBB as well as in cancer cells which may vary from patient to 
patient. Hence the formulation herein is based on the premise that by modifying the 
theranostic liposomes with the two ligands, i.e. Tf & Lf, it is possible to minimize the 
drawbacks observed in using the single ligands. The basis is that the dual modified 
thernostics will be less identified compared to Lf-tagged particles by macrophages, will 
have lower effect on TfR expressing major normal tissues, and will have the potential to 
cross the BBB through TfR, LfR and Tf & LfR depending on the level of expression of 
these receptors on a given glioma cell. 
On top of efficiently targeting tumor cells, theranostics should incorporate 
excellent contrast agents. Water-soluble derivatives of gadolinium-containing 
metallofullerenes, Gd3N@C80, having 10.8 μB - 21 μB effective magnetic moment 
(μeff) values [161, 162] are excellent candidates for MRI. Further, magnetization curves 
of Gd3N@C80 at different temperatures shown no hysteresis indicating Gd3N@C80 as a 
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completely paramagnetic molecule [163]. These molecules are also characterized by 
higher r1 relaxivity, mainly, when designed to be water soluble. For example, 
Hydrochalarone-6 functionalized  Gd3N@C80  shown r1 relaxivity of 205 mM-1 s -1 (68 
mM-1 s -1 Gd, compared with 3.8 mM-1 s -1 for Magnevist [164]). Gd@C82(OH)40 , with 
just one Gd+ was reported to have significantly higher r1 relaxivity (67 mM-1s-1)  than Gd-
DTPA [165]. 
The purpose of this work was therefore to develop a new targeted theranostic that 
incorporates imaging and therapeutic entities within the same GBM-targeted molecule. A 
liposome-based carrier vehicle was used to incorporate the anti-cancer drug doxorubicin 
(DXR) and Gd3N@C80 which was proven to provide excellent MRI contrast in different 
studies [53, 166, 167]. The liposome was then dual tagged with Tf and Lf and tested for 
efficacy in vitro. This strategy may provide a better way to diagnose and treat GBM.  
III.3 Materials and Methods  
III.3.1 Materials then reagents 
Liposome components L-α-phosphatidylcholine (Egg, Chicken) (EGG-PC), 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N- [methoxy (polyethylene glycol)-
2000] (PEG200PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [amino 
(polyethylene glycol)-2000] (DSPE-PEG (2000)-NH2), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N- [carboxy (polyethylene glycol)-2000] (DSPE-PEG (2000)-
COOH) and Cholesterol were purchased from Avanti polar lipids. N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) and N-
Hydroxysuccinimide (NHS) for protein-liposome conjugation, DXR-HCl (cancer drug), 
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Lf human and Tf for targeting liposomes were purchased from Sigma Aldrich. Dialysis 
cassettes at 2000 and 3500 Kd molecular weight cut-off to remove un-encapsulated 
materials; Vybrant® MTT Cell Proliferation Assay Kit for cell viability test and Novex™ 
8% Tris-Glycine Mini Gels for western blotting were purchased from Thermo Fisher 
Scientific. Gadolinium (Gd), a standard for induced coupling plasma spectrometer 
measurements, was purchased from Fisher Scientific. Gd3N@C80-OH and Gd3N@C80 
were purchased from Luna Innovations [53, 164]. The G1/221/12 mouse anti-human Tf 
receptor primary antibody was from Developmental Studies Hybridoma Bank. Rabbit 
anti-mouse secondary antibodies were from Thermo Fisher Scientific. 
III.3.2  Cell culture, real time PCR (RT-PCR) and Western blots 
U251-MG cells were grown in Eagle's Minimum Essential Medium (EMEM) 
supplemented with 2 mM Glutamine, 1% non-essential amino acids, 1 mM Sodium 
Pyruvate and 10 % fetal bovine serum (FBS). Cells were maintained at 37 °C in the 
presence of 6% CO2. 
The expression of targets in U251-MG cells were verified using PCR [168]. 
Briefly, total cellular RNA was isolated using the one-step RNeasy mini-kit (Qiagen, 
Valencia, CA) according to the manufacturer’s procedure [169] and primers, sequences 
shown in Table 4, are generated using Primer-BLAST as described in [170]. PCR 
reactions were performed by setting a reverse-transcription reaction temperature of 50 °C 
(30 min) and an initial PCR activation temperature of 95 °C (15 min). The 3-step cycling 
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conditions were set to 94 °C (45 secs), 54 °C (30 secs) and 72 °C (1 min) for denaturing, 
annealing and extension respectively (30 cycles). Finally, products were run in 2% gel.  
The expression of Tf receptor was verified using Western blotting as described 
[171]. Briefly, U251-MG lysates proteins were separated by SDS-PAGE, transferred onto 
nitrocellulose, and probed with 0.3 µg/ml mouse anti-human anti-transferrin receptor 
antibody. After washing HRP-conjugated rabbit anti-mouse antibody (0.4 µg/ml) was 
added for an hour, washed, and bands visualized using clarity Max™ Western ECL 
Blotting Substrate mixture on Amersham Imager 600 (Figure 3).  
 
Table 4. Forward and Reverse Primers Sequences used for the Real Time Polymerase 
Chain Reactions. TfR-Transferrin receptor, DAG-Dystroglycan, EGFR-Epidermal 
growth factor receptor, FABP7-Fatty acid binding protein 7, Interleukin receptor subunit 
α 2, Lactoferrin and platelet derived growth factor receptor (PDGFR). 
 
 Protein  Forward & Reverse primer (FP & RP) sequence 5’->3’ Tm 
TfR FP AGGACGCGCTAGTGTTCTTCTG + 62.59 
 RP CATCTACTTGCCGAGCCAGG - 60.53 
DAG FP CCCAGTACGTCAAGACCCTG+ 59.75 
 RP GCACACAGAGCATTAGAAGCC- 59.60 
EGFR FP TTGCCGCAAAGTGTGTAACG+ 59.97 
 RP CGATGGACGGGATCTTAGGC- 60.04 
FABP7 FP AGAAACTGTAAGTCTGTTGTTAGCC+ 59.24 
 RP TCTGCCCAGAACTTGTGTAACT- 59.56 
IL13RA2 FP GCGGGGAGAGAGGCAATATC+ 60.04 
 RP GATAGACTGGCGGCAAAGGT- 60.11 
PDGFR FP GCTGTTACCCACTCTGGGAC +  60.04 
 RP TGGTGTCCTTGCTGCTGATG - 60.61 
LTF FP GTGCCATTGCAACCCTTGTC+ 60.32 
 RP GAGTTCGTGGCTGTCTTTCG- 59.2 
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Figure 3. Testing Target Expression Using RT-PCR & Western Blots. A) RT-PCR 
Analysis on Agarose Gel Electrophoresis of total RNA Extracted from U251-MG cells 
Demonstrates the Expression of DAG1, EGFR, FAB7, IL13Rα2, LTF and TfR. B) 
Western Blots on 8% tris-glycine Gel-electrophoresis were probed with G1/221/12 
Mouse Anti-Human Tf Receptor Primary Antibody followed by HRP Tagged Rabbit 
Anti-Mouse Secondary Antibody and Imaged Using Amersham Imager 600.  
 
 
III.3.3 Liposome preparation and characterization 
III.3.3.1 Liposomes preparation 
Gd3N@C80 free as well as Gd3N@C80 encapsulated liposomes were formulated by 
disolving, EGGPC + Chol (8.1:1.75), EGGPC + Chol + Gd3N@C80 (8.1:1.75:0.5), 
EGGPC + Chol + PEG2PE + Gd3N@C80 (7.1:1.75:1:0.5) and EGGPC + Chol + 
AmineDSPE + Gd3N@C80 (7.1:1.75:1:0.5) mg ratios in 5 ml chloroform. After removing 
the organic solvent, the lipid layer was subjected to hydration using 300 mM 
(NH4)2HPO4 solution at 7.4 PH, then vortexed and sonicated until the lipid layer was 
completely dissolved in the hydrating medium. The multi-laminar vesicles (MLV) were 
extruded through 400 -100 nm filters respectively. Free molecules, those not part of the 
formulated liposomes, were removed using a 2 Kd molecular weight cut off dialysis 
cassette immersed in HEPES saline solution (140 mM NaCl, 10 mM HEPES buffer). 
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DXR was loaded (0.25 mg/ml) remotely by incubating the liposomes & DXR in a 7 °C 
saline HEPES buffer (Figure 4). 
Gd3N@C80-OH encapsulated, PEGylated liposomes composed of EGGPC: 
CHOL: PEG2PE: DSPE-PEG2K-NH2 (53:43:4:1) or EGGPC: CHOL: PEG2PE: DSPE-
PEG2K-Amine: DSPE-PEG2K-COOH (53:43:4:0.5:0.5) were formulated as shown in 
Figure 4 [172-175]. Briefly, lipids dissolved in chloroform were evaporated using rotary 
evaporator to form a thin lipid film followed by hydration with 250 mM ammonium 
sulfate and Gd3N@C80-OH (1.4 mg/ml) solution adjusted to a 5.4 PH (4 °C) which 
results in multilamellar vesicles (MLV). The liposomes were resized using an Avanti 
mini extruder passing seven times through 200 and 100 nm pore diameter polycarbonate 
filters respectively.  
Next, liposomes were conjugated with proteins using EDC/NHS chemistry. 
Briefly, 748 mg of EDCI and 1.13 mg of NHS were added to 3 different 1 ml carboxylic 
functionalized liposomes and the mixture was gently stirred for 10 min at room 
temperature. Mono-tagged liposomes were formulated by adding equal amount of Tf and 
Lf (5 mg) to the two 1 ml suspensions respectively and the mixture was kept for 3 h at 
room temperature. For a dual tagging process, an equal amount of protein (half each) was 
mixed with COOH-functionalized liposomes for the same period as in the case of mono-
tagged liposomes. Unattached proteins were removed using dialysis cassette immersed in 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) saline buffer for overnight. 
The attachment of proteins to the liposomes was confirmed as described below. Lastly, 
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0.44 mg of DXR was added to 1 ml of each class of liposomes (for a lipid concentration 
of 6.54 mg/ml, the final DXR concentration was 0.76 mM). After a through mixing, the 
suspensions were incubated at 40 °C in a water bath and intermittently shaken for 20 min 
to produce DXR and Gd3N@C80 encapsulated liposomes.  
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Figure 4. A Flowchart Indicating the Formulation and Tagging of DXR and Gd3N@C80-OH Loaded Liposomal Theranostics.  
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III.3.3.2 DXR and Gadolinium quantification 
The amount of DXR inside the liposomes was measured using Biotech 
MX/Mono-based Microplate Reader. First, an absorbance standard curve was established 
for 12.5, 6.25, 3.125 and 1.5625 µg/ml DXR at 475 & 580 and 470/570 nm excitation 
and emission wavelengths. The DXR concentration inside the protein tagged liposomes 
was estimated by measuring the absorbance, after lysis with methanol, and using the 
standard curve equation. The encapsulation efficiency of the liposomes was calculated 
using the equation (EE= (Winside / Wtotal) X 100) where Winside is the inside liposome DXR 
concentration and Wtotal is the initial DXR concentration. Similarly, the amount of Gd 
was estimated via inductively coupled plasma optical emission spectrometry (Varian 710-
ES ICP). Briefly, the Gd3N@C80 encapsulated liposomes were diluted to 3 ml (3% nitric 
acid) and the emission intensity of Gd in the sample was measured together with the 
emission intensity of standard Gd concentrations. The final amount of Gd (Gd3N@C80) 
inside the theranostics was estimated from the standard curve equation developed for 
known concentrations. The encapsulating efficiency was calculated using (EE= (Winside / 
W total) X 100) where Winside is the concentration of Gd inside the theranostics and W total 
is the total concentration of Gd in functionalized and non-functionalized stock 
Gd3N@C80 solution used for hydration (formulation). 
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III.3.3.3 Characterization using TEM, UV-VIS and FTIR spectra  
The spherical assembly of the liposomes was examined using transmission 
electron microscopy (Carl Zeiss Libra 120 plus TEM Microscope). Briefly, TEM grids 
were sputter coated using a Leica Ace Sputter coater. Then the grids were immersed into 
the sample, air dried, and the particles were examined at several magnifications. UV-VIS 
spectroscopic absorbance was measured to assess the attachment of proteins to 
liposomes. Similarly, FTIR spectra were measured to confirm the targeting process and to 
evaluate the presence of functional groups associated to the liposomes and ligands. For 
this purpose the symmetric/asymmetric stretch of CH2 (around 2850 cm−1, 2920-2960 
cm-1 respectively), the carbonyl stretching mode C=O (1800–1680 cm−1) and the 
phosphate head group vibration regions (1260–1000 cm−1) [176] are considered to 
monitor liposome components. The existence and modification of amine/carboxylic 
functional groups, before and after tagging the liposomes with proteins were assessed by 
evaluating the N-H stretch, N-H bend and C-N stretch occurring at 3300-3500, 1600 and 
1080-1360 cm-1 wavenumbers. Similarly, the presence of carboxylic acid was assessed in 
the 1725-1700 cm-1 region [176].  
III.3.3.4 Size and zeta potential measurements 
The size and zeta potential of the liposomes were measured using Malvern 
zetasizer and Brownian motion of the liposomes was captured using Nanosight nano-
tracking analysis. For zetasizer measurements, liposomes were diluted with water (at 
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0.1/0.9 ratio) and the refractive index, the viscosity and dielectric constants of the 
dispersant were set to 1.33 (at 25 °C), 0.87 cP and 78.5, respectively. As the average size 
and zeta potential values alone may not be informative enough, the quality control 
correlation graphs as well as the corresponding size and zeta potential values are 
presented. The particle size was also measured using NanoSight LM10 device mounted 
on an optical microscope at 20 X objective and the Brownian motion of the liposomes 
was captured at room temperature and is provided as supplementary material.  
III.3.4  Cytotoxicity  
The cytotoxic effect of the theranostic on U251-MG cells was examined using the 
MTT assay. U251-MG cells were seeded in triplicate for 72 hours in a 96-well plate at a 
density of 2.8 X 104 cells per well. After the cells reached confluency, the theranostic or 
controls were added (12 µg/ml DXR in 100 µl) in cell culture medium. The first groups 
of control cells were treated with equal volume of DXR-free liposomes. Positive control 
cells were also treated with an equal concentration of free DXR (no liposomes), 12 
µg/ml, and another group of wells were left untreated to serve as negative controls. After 
72 hours of treatment, the cell viability was determined by MTT method as described in 
the Vybrant MTT cell proliferation assay kit according to the manufacture's protocol 
[177].  
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III.3.5 Statistical analysis 
Statistical analyses were performed using Excel. The variances between the 
samples were analysed and significance levels were calculated using Student’s t-test (*p< 
0.05, **p<0.01, ns p>0.05) and data are presented as mean ± standard deviation. 
III.4 Results and Discussions 
III.4.1 RT-PCR and Western blot 
The expression of genes and proteins on a cell line could be affected by culturing 
condition, the number of passaging etc. Furthermore, issues on U251-MG and U373-MG 
cell lines were reported where the cell lines might no longer reflect the original tumors 
that they are supposed to represent [178]. Therefore, the expression Tf receptor in U251-
MG along with other potential targets was tested using RT-PCR. The test confirmed the 
expression of Tf-receptor (TfR), IL13Rα2, EGFR, DAG1, FABP7 and LTF genes on the 
cell line and a control receptor that is not (or very less) expressed in U251-MG cells 
PDGFR [100] (Figure 3). Western blotting also revealed the expression of TF receptor on 
U251-MG cells with 85KD band marker. Furthermore, the intensity of the western blots 
increases with cell concentration across the lanes confirming the presence of the receptor 
on U251-MG cells.  
III.4.2 Liposome development and characterization 
III.4.2.1 Characterization using TEM, UV-VIS & FTIR  
TEM images of the liposomes at different magnifications confirmed the spherical 
assembly of the liposomes (Figure 5). The UV-VIS and FTIR spectra measurements 
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support the successful conjugation of proteins to the liposomes as depicted by a clear 
difference in the absorbance signatures of those proteins tagged liposomes compared to 
non-tagged counterparts. Proteins absorb UV light at 280 and 200 nm, due to the 
absorption of aromatic amino acids and the absorption of peptide bonds respectively. 
Several authors have reported UV-VIS signatures of Tf [179] and Lf (Fig 1 A of [180]) 
and both ligands have similar relatively higher absorption at 280 nm. As Tf and Lf are 
proteins of the same family with similar shape, similar absorbance signatures were 
anticipated around 280 nm in Tf-tagged, Lf-tagged as wells as Tf+Lf tagged 
formulations. As anticipated, a clearly evident higher absorption at nearly 290 nm 
wavelength, on the UV-VIS spectra in protein-tagged liposomes is observed compared to 
the absorbance signature of the non-tagged liposome (Figure 6). A high absorption 
around 230 nm wavelength is in agreement to previously reported UV-VIS liposomes’ 
signatures [181, 182] and a relatively amplified absorption around 280 nm are consistent 
with an extinction measurement of Tf attached liposomes reported in [182].  
The presence of PEG in the PEGylated liposomes is supported by FTIR 
absorbance around 2880 cm-1 due to a C-H stretch of PEG (Figure 7) [183]. CH2 
asymmetric stretching near 2925 cm−1 and symmetric stretch near 2850 cm−1 , CH2 
scissor and bend at 1460 and 1420 cm-1 respectively are in agreement with previous 
EGGPC signatures [184]. PO2 asymmetric stretching near 1220 cm−1 and symmetric 
stretch at 1088 cm-1 (Figure 7) are also in agreement with previously reported signatures 
of EGGPC or EGGPC/Cholesterol liposomes [184]. Those signatures support unaffected 
and non-modified EGGPC in the liposome particles. As in the case of the UV-VIS 
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spectra, the FTIR signatures also support the tagging process. The peak near 1650 cm-
1 in the FTIR signature of protein tagged liposomes could be related to amide I band 
associated with a C=O stretching vibrations of peptide bonds. The peaks near 1540 cm-
1 (N-H bending vibration/C-N stretching vibration) and 1240 cm-1 (C-N stretching 
vibration/N-H bending vibration) could be due to the amide II band and amide III bands, 
respectively (Figure 7). The peak near 3300 cm-1 can also be N-H bending vibration and 
the peak near 1400 cm-1 from protein side-chain of COO- and are indicated maximum in 
the protein tagged liposomes. The highest amplitude on 3300-2500 cm-1 depicted on 
non-tagged liposomes compared to protein tagged liposomes may show a modification of 
the carboxylic functional group, in the later, during the conjugation process (Figure 7). 
The higher amplitudes between 1320-1210 cm-1, typical wave number range for C-O 
stretch, in non-tagged liposomes than on protein tagged ones may indicate the 
modification of carboxylic functional group. NH stretch at 3288 cm-1 clearly visible on 
Lf, Tf, Lf and Tf tagged liposomes compared to non-tagged counterparts is likely from 
secondary amines (Figure 7). These results, in general, support the conjugation of the 
liposomes with the proteins. 
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Figure 5. Transmission Electron Microscope Images and Brownian Movement Analysis 
Support the Formulation of Stable Liposomes. In the left panel TEM images of (EGGPC 
+ Cholesterol) Liposomes, main lipid components of all Liposomes, at (A) 4,000 X, (B) 
12,500 X, (C) 20,000 X and (D) Gd3N@C80 at 160,000 X. In the right column, (A) a 
snapshot of a video capturing Brownian Motion analyzed using Nanoparticle Tracking 
Analysis (NTA), and (B) corresponding size distribution versus intensity of Gd3N@C80 
loaded Liposomes. A video file of the particles moving under Brownian motion is also 
provided in supplementary information 1.  
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Figure 6. UV-Vis Spectra Support the Formulation of Protein Tagged Theranostics. Tf 
tagged liposomes are indicated in purple, Lf tagged liposomes (red), dual-tagged (Lf and 
Tf) liposomes (brown) and non-tagged liposomes indicated in green. The presence of 
absorbance amplitude change is evident on protein tagged liposomes compared to that of 
non-tagged liposomes. 
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Figure 7. FTIR Spectra Support the Tagging and PEGylating of Theranostic Liposomes. 
The FTIR Absorption Spectra of Protein tagged Liposomes compared to non-tagged are 
indicated after subtracting the buffer spectra. FTIR scanning parameters were set to 4 
scans at 4 cm-1 resolution covering 400-6,000 cm-1 wavenumber range (for a detailed 
explanation of the absorbance see sections 2.5 and 3.6). The smoothed version of the 
original figure (top) is shown at the bottom. 
 
 
III.4.2.2 Encapsulation efficiency 
A scatter plot and correlation based encapsulation efficiency predictions 
confirmed successful loading of the liposomes with DXR as well as with Gd3N@C80 
particles (Figure 8). DXR encapsulation efficiency of non-functionalized Gd3N@C80 
containing liposomes formulated using ammonium phosphate hydration process was 94% 
and accords the encapsulation efficiency reported in [175]. However, the non-
functionalized Gd3N@C80 encapsulation efficiency was low (2%). In an attempt to 
increase Gd3N@C80 encapsulation efficiency, OH-functionalized Gd3N@C80 dissolved in 
ammonium sulphate solution was used for the hydration process. In the later approach, 
Gd3N@C80 encapsulation efficiency of the liposomes was increased to 13%. After DXR 
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loading and targeting these functionalized Gd3N@C80 containing liposomes, the DXR 
encapsulation efficiencies were 45%, 57% and 46% respectively for (Tf + Lf), Tf and Lf 
tagged liposomes. 
 
 
 
Figure 8. Standard Curves to Estimate DXR and Gd Encapsulation Efficiencies. A) A 
linear Standard Curve used to predict Gd3N@C80-OH Encapsulation Efficiency in 
Liposomes. Emission Intensity of different concentrations of Gd standards dissolved in 
3% HNO3 solvent matrix were measured using ICP and Gd3N@C80 was predicted from 
the correlation equation. B) A linear Standard Curve equation used to predict gadolinium 
concentration in Gd3N@C80-OH solution. C) Linear Standard Curve used to predict DXR 
Encapsulation Efficiency of targeted Theranostic Liposomes. DXR excitation and 
absorption were set to 470 & 570 nm wavelengths respectively. 
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III.4.2.3 Size and zeta potential measurements 
The average hydrodynamic size of non-tagged liposomes was 146 nm (Table 5) 
and after the tagging process it was 148, 142, and 148 for Tf, Lf and (Tf + Lf) tagged 
liposomes respectively (Table 5, Figure 9). After the liposomes are loaded with DXR, the 
average hydrodynamic sizes were 139, 142 and 149 nm for Tf, Lf and Tf + Lf tagged 
theranostics respectively (Table 5). The size differences observed after loading with DXR 
could be due to additional processes such as the remote loading and dialysis. The 
polydispersity index (PDI) values for most of the formulations are within 0.2 suggesting a 
narrow size distribution range. Approximately 70% of the liposomes are 60-80 nm in size 
(Figure 10). Such smaller-size liposomal formulations depicted by single as well as dual 
tagged and PEGylated particles are predicted to have less interaction with plasma 
proteins, i.e. their smaller sizes will help evaded a capture by the reticuloendothelial 
system (RES), may ensure longer half-life in the blood, and have a potential to 
accumulate at the tumor site [185]. These size distributions are also in accord with the 
size of nanoparticles reported to cross the BBB and got accumulated in the brain [186, 
187]. The average zeta potential of Gd3N@C80 loaded non-tagged liposomes at 7.4 PH 
was -19 mV and after targeting it was -14, -16 and -17 mV for Tf, Lf, and Tf + Lf tagged 
liposomes respectively (Table 5, Figure 11). After the drug loading process, the average 
zeta potential was -19, -17 and -15 mV respectively for Tf, Lf and Tf +Lf tagged 
liposomes at the same PH (Table 5, Figure 11). The zeta potential values in this study are 
in accord with the zeta potential values reported being effective for brain delivery [187-
189]. 
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Table 5. Zeta Potential, Average Hydrodynamic Diameter and Polydispersity Index of 
Single, Dual and Non-tagged Liposomes Loaded with Gd3N@C80-OH and DXR. 
Gd3N@C80-loaded represent devoid of DXR and ((DXR + Gd3N@C80)-loaded) contains 
both. 
  
Liposome type Zeta 
Potential 
(mean ± SD 
mV) 
Average 
Size 
(mean 
nm) 
PDI 
Tf -tagged- (Gd3N@C80-loaded) -14.7±1.07 148.3 0.215 
Lf- tagged- (Gd3N@C80-loaded) -16.5 ±1.04 142.2 0.257 
(Tf +Lf)-tagged- (Gd3N@C80-loaded) -17.1±1.27 148.7 0.218 
Non-tagged-(Gd3N@C80-loaded) -19.8 ±1.56 146.3 0.220 
Tf -tagged - ((DXR + Gd3N@C80) -loaded) -19.9 ±0.81 139.4 0.204 
Lf- tagged - (DXR +Gd3N@C80-loaded) -17.6±1.31 142.4 0.184 
(Lf+ Tf)- tagged - (DXR +Gd3N@C80-loaded) -15.5±0.61 149.3 0.212 
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Figure 9. DLS Size Measurements and Size Distribution Analysis of (Gd3N@C80 + DXR) 
Loaded-Targeted Liposomes versus (Gd3N@C80 only) Loaded-Targeted Liposomes 
Support the Formulation of Stable Theranostics. A) Example of correlation coefficient 
graph of (Tf + Lf) tagged, Gd3N@C80 and DXR loaded liposomes at the top with 
corresponding size distributions indicated at the bottom. B) An overlay of size 
distribution versus intensity of Lf-tagged Gd3N@C80 & DXR loaded (blue), (Lf + Tf)-
tagged Gd3N@C80 &DXR loaded (black), Tf-tagged Gd3N@C80 and DXR loaded (green) 
and non-tagged liposomes portrayed in red are shown at the top. At the bottom, an 
overlay of Size distribution versus intensity of Lf-tagged Gd3N@C80 loaded (green), (Lf 
+ Tf)-tagged Gd3N@C80 loaded (blue), Tf-tagged Gd3N@C80 loaded liposomes (red) and 
non-tagged liposomes are represented in black.  
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Figure 10. The Size Distribution of Liposomes by their Number Confirms that Most 
Nanoparticles Possess < 100 nm Hydrodynamic Diameter. A) Lf + Tf tagged Gd3N@C80 
& DXR loaded, B) Tf tagged Gd3N@C80 &DXR loaded, C) Lf tagged Gd3N@C80 + DXR 
loaded liposomes.  
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Figure 11. Zeta Potential Measurements Support the Formulation of Stable, at 
Physiological PH, Drug and Imaging Agent Containing Liposomes. A) Example phase 
plot of (Tf + Lf) tagged, Gd3N@C80 and DXR loaded, liposomes shown at the top with 
corresponding apparent zeta potential given at the bottom. B) An overlay of zeta potential 
distribution of (Gd3N@C80 + DXR) loaded liposomes shown at the top where non-tagged 
liposomes portrayed in red, Lf-tagged liposomes (black), (Lf + Tf)-tagged liposomes 
(blue), Tf tagged liposomes (green) & an overlay of zeta potential distribution of 
Gd3N@C80 only loaded liposomes shown at the bottom where non-tagged liposomes are 
represented in black, Lf tagged liposomes (green), (Lf + Tf) tagged (blue), Tf tagged 
liposomes represented in red.  
 
 
III.4.3  In vitro evaluation 
Tf and Lf are quite similar in sequence and structure and coordinate iron in the 
same manner, but they differ in their affinities for iron as well as their receptor binding 
properties [190]. While Tf is known to couple with Tf receptor, Lf is suggested to couple 
with its own receptor [191] but also with Low density lipoprotein receptor-related protein 
1 (LRP1) and LRP2 [192]. The difference in the expression of levels of TfR and LfR is 
more pronounced in U251-MG cells compared to the expression levels in other glioma 
cells such as U87-MG [101]. As the difference in the magnitude of TfR and LfR 
(example LRP1) expression in U87-MG is not clear (the protein atlas [193]), U251-MG 
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was selected for the in vitro evaluation. As shown in Figure 9 A, the viability assay is in 
line to the expression level of the receptors in U251-MG. Tf-modified theranostics are 
more toxic followed by (Tf+Lf) and then Lf-tagged. (Tf+Lf)-modified are less toxic, 
mainly, because they possess half of the Tf in Tf-modified theranostics. However, it is 
critical to notice that (Tf+Lf)-modified theranostics also reduced the cell viability 
significantly (Figure 12). As DXR-free liposomes never induce a significant negative 
effect on the metabolic activity of the cells, viability reductions observed in Tf-tagged 
and (Tf + Lf)-tagged theranostics treated cells are most likely due to DXR and these 
results in line to the viability reductions observed in free DXR treated cells (Figure 12). 
Therefore, one reason for the difference in toxicity (i.e. for the reductions in metabolic 
activity of the cells) is the degree of expression of the receptors targeted by the ligands. 
The expression of LRP1 and intelectin1 (ITLN1) is quite low and no LRP2 expression is 
observed on U251-MG cells (the protein atlas [193]).  
Keeping the differences in the degree of expression of these receptors on U251-
MG cells and the proportion of Tf in the theranostics, a higher toxicity of Tf-tagged 
theranostics compared to Lf-tagged theranostics support the notion that the mechanism of 
delivery is indeed receptor mediated. The cell viability reductions in (Lf + Tf)-tagged 
theranostics treated cells (73%) corroborate with the lower viability recorded in cells 
treated with Tf-tagged theranostics (41%) and in Lf-tagged theranostics treated cells 
(92%). The viability assay, shown in Figure 12 A, is also in line with the light 
microscope visualization taken after the treatments (Figure 12 B). Free DXR, Tf-tagged 
as well as (Tf + Lf)-tagged theranostics resulted in lower cell proliferations compared to 
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untreated controls. These results support the hypothesis that (Tf + Lf)-tagged theranostics 
have the potential to specifically kill TfR expressing cancer cells. The superiority of the 
dual modification compared to single modified counterparts is that it would be less toxic 
to major organs that express TfR while killing the cancer cells which express TfR, LfR or 
both TfR & LfR to a larger extent. 
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Figure 12. MTT Cell Viability Assay Confirms the Cytotoxic Effect of Single (Tf) and 
Dual tagged (Tf + Lf) Theranostics on U251-MG cells. The cell viability is indicated in 
percent after 72 hrs. incubation of U251-MG cells with Tf & Lf tagged (Tf + Lf), Tf 
tagged (Tf), Lf tagged (Lf) liposomes all loaded with Gd3N@C80 & DXR; blank 
liposomes (loaded with Gd3N@C80 but devoid of DXR) and free DXR (non-encapsulated 
DXR). The untreated cells were set to 100% (controls) cellular viability. These results are 
representatives of three independent experiments and the data values are expressed as the 
mean ± standard deviation (SD), n=3. B) A comparison of U251-MG cells treated with 
DXR free liposomes with respect to those treated with DXR loaded liposomes supported 
the cytotoxic effect of the theranostics on glioma cells. Cells treated with targeted 
liposomes loaded with DXR and those treated with free DXR shown low viability as 
depicted with light microscope visualizations of the cells after 72 hrs. of the treatment. 
The images from right to left represent U251-MG cells treated with TF tagged 
(Gd3N@C80 & DXR loaded), LF tagged (Gd3N@C80 and DXR loaded), TF + LF Tagged 
(Gd3N@C80 &DXR loaded liposomes), free DXR, blank liposomes (Gd3N@C80 loaded 
but DXR free), and untreated cells. 
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III.5 Conclusion 
Search for new therapeutics and diagnostics for GBM, the deadliest brain tumor, 
has been a higher priority. In this chapter novel, theranostic liposomes tagged with both 
Lf and Tf (1:1 ratio) are constructed for the first time to harness the potential of crossing 
the BBB and kill transferrin receptor expressing GBM and glioma stem cells. These dual-
tagged theranostics contain DXR and a novel imaging agent (Gd3N@C80-OH) and are 
PEGylated. Furthermore, > 70% of these theranostic liposomes possess 60-80 nm 
diameter and have < 0.2 polydispersity index which signifies narrow particle-size 
distribution. Encapsulation efficiency, zeta potential, FTIR and UV-VIS measurements 
support the formulation of DXR & Gd3N@C80-OH loaded, targeted and stable liposomes 
at physiological PH. These dual-tagged theranostics exhibited improved inhibitory effects 
in U251-MG cells compared to Lf mono-tagged counterparts. The results of this study 
demonstrated that DXR and Gd3N@C80-OH loaded and Lf & Tf dual-tagged, PEGylated 
liposomes might be potential drug and imaging agent delivery systems for GBM 
treatment.  
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CHAPTER IV 
 
ASSESSING THE STRUCTURAL STABILITY OF GD3N@C80 AND 
GD3N@C80(OH)42  CONTAINING LIPID BI-LAYERSIN                               
PHYSIOLOGICAL SOLUTIONS USING                                                         
MOLECULAR DYNAMIC                                                                        
SIMULATIONS 
 
 
IV.1 Abstract  
Gadolinium (Gd) loaded fullerenes are potential MRI components of future 
theranostic liposomes due to their higher relaxivity, up to 25 fold higher, compared to 
traditional contrast agents. However, the dynamics and structural stability of Gd3N@C80 
containing lipid bilayers in physiological salt solutions and the interactions of Gd3N@C80 
with the lipid bilayer constituents are uncertain. In this chapter, the structural stability of 
C80 & C80(OH)42 containing lipid bilayers constructed from POPC, DSPE, cholesterol 
(CHOL) and solvated in KCl, NaCl and CaCl2 solutions are evaluated using molecular 
dynamic simulations. To this end, root means square deviations (RMSD), area per lipid 
(APL), radial distribution function (RDF) of ions, number density profiles (NDP), order 
parameters (SCD), lipid bilayer thickness (LBT) and lipid interdigitations (LI) are 
calculated to assess the effect of the molecules on the stability of the lipid bilayer 
structure or vice versa.  Further, the dynamics of the fullerene cages across different 
regions of the lipid bilayers are studied using steered molecular dynamic simulations    
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(SMD). The results indicate that C80 & C80(OH)42 remains structurally stable throughout 
the simulation windows. Furthermore, the molecules moved off the center towards the 
lipid head groups but never induced substantial structural instability of the bilayers. 
Carbon-deuterium order parameter (SCD) simulations indicated that lipids residing closer 
to C80 (< 20 Å) have lower lipid order compared to lipids residing closer to C80(OH)42. 
However, the overall lipid bilayer (LBL) structures remain stable throughout the 
simulation windows. The energy required to displace C80(OH)42 across the lipid bilayer is 
found to be higher than the energy required to displace C80, partly, due to hydrogen 
bonding of the former with POPC in the lipid bilayers. These results support the 
hypothesis that OH-functionalized fullerene cages and thereby OH functionalized Gd-
fullerene containing liposomes to be stable in physiological salt solutions.  
IV.2 Introduction  
As discussed in the previous chapters, Gd-loaded endofullerenes such as Gd@C82 
and Gd3N@C80 have attracted much attention as potential magnetic resonance imaging 
(MRI) contrast agents, given their inherent higher 1H relaxivity compared to most 
commercial contrast agents [194]. Moreover, the fullerene cage is predicted to be stable 
and thus prevent toxic Gd ions from being released [179]. Thus, their use as the 
diagnostic component of new molecular species continues to grow [53, 167, 195]. 
In spite of the numerous in-vitro and in-vivo studies on Gd3N@C80 incorporated 
into liposomal formulations, computational studies to explore the localization and the 
interaction of functionalized or non functionalized C80 with liposome-lipids are 
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uncommon. The very few molecular dynamics simulations that explored the interactions 
of fullerenes and their derivatives with lipid bilayers include those reported in [196, 
197]. However, these studies focus on the interaction of C60 with lipid membranes 
developed from single lipid (dipalmitoylphosphatidylcholine, DPPC) and their 
approaches mainly focus on the potential mean of force analysis. To my knowledge, there 
are no reported molecular dynamic simulations based structural stability study of C80 and 
its derivative containing lipid bilayers in physiological salt solutions. Furthermore, 
molecular dynamics simulations based studies are essential as experiments associated 
with phospholipids and Gd endofullerenes are expensive. 
The aims are: 1) to investigate the stability of Gd3N@C80 and Gd3N@C80(OH)42 
inside lipid bilayers by exploring structural variations of the outer compartments i.e. C80 
& C80(OH)42 inside lipid bilayers that are immersed in different physiological salts. 2) To 
study the effect of these molecules on the structural stability of lipid bilayers or vice 
versa. 3) To evaluate the localization preference of C80 and C80(OH)42 through energy as 
well as force computations by applying steered molecular dynamic simulations using 
NAMD. To this end, structural stabilities of different C80 containing lipid bilayers, 
mainly composed of the lipids tested in the last chapter, are investigated by analyzing the 
RMSD of the molecules, ND profiles, SCD of lipid chains, LI analysis to assess 
correlation based leaflet overlap and number of atoms in contact, LBT computations and 
RDF of cations/anions with respect to lipid head groups by immersing the different lipid 
bilayers in 0.15 M of NaCl, KCl and CaCl2 solutions.  
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IV.3 Materials and Methods 
The structure information of fullerene isomer (C80) was downloaded in XYZ 
format from [198, 199]. From the XYZ file, mol2 and protein data bank (PDB) files were 
generated using Open Babel GUI chemical toolbox. Finally, Gd3N@C80, 
Gd3N@C80(OH)42 and C80(OH)42 were created using ChemSketch and SYBYL-X 2.0 
software (Figure 13). To investigate the effect of Gd3N on the structures of Gd3N@C80 or 
Gd3N@C80(OH)42, Gd containing and Gd-free counterparts were energy minimized using 
SYBYL-X 2.0 in Tripos force field by applying a conjugate gradient method for 100 
iterations (Table 6).  As the lipids used for the theranostics in the last chapter include egg 
L-α-phosphatidylcholine (EGGPC), polyethylene glycolphosphatidyl ethanolamine 
(PEGPE) and CHOL and since 1-palmitoyl-2-oleoyl PC is a major constituent of 
EGGPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) is considered as an 
excellent synthetic substitute for EGGPC [200]. Further, POPC mimic mammalian 
phospholipids such as EGGPC for it has a saturated chain in its Sn-1 leg and unsaturated 
chain in its Sn-2 leg. Hence POPC, major component of the lipid bilayers herein, is 
mixed with CHOL and DSPE at 85:10:5 fractions.  
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Figure 13. Molecular Structures of C80 and its Derivatives Considered for The Study. The 
figures represent, (A) Gd3N@C80, (B) Gd3N@C80(OH)42, (C) C80 and (D) C80(OH)42. All 
are generated using Chemsketch and converted to PDB and mol2 formats using Open 
Babel software. SYBYL-X 2.0 was used for energy minimization processes using Tripos 
force field by applying a conjugate gradient method for 100 iterations. The minimization 
energy values of each component are given in Table 6. 
 
 
IV.3.1  Lipid bilayer structure descriptions 
First, CHARMM parameter (Equation 1 below) and topology files for 
functionalized and non-functionalized fullerenes were generated using [201]. Then, C80 
and C80(OH)42 containing lipid bi-layers were generated using [202] as follows. C80 and 
C80(OH)42 were uploaded in PDB format setting the Z axis as the lipid bilayer normal and 
the center of the lipid bilayers as the origin of the systems. The fullerenes were positioned 
at the origin and aligned along the Z axis. The overall lipid bilayer structural assemblies 
A B 
C D 
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in different physiological salt solutions considered herein are given in Figure 14 & Table 
7. In general, the lipid bilayer systems are 10 X 10 nm width consisting of 32 CHOLs, 
272 POPC and 16 DSPE equally distributed in the upper and lower leaflets. The average 
size of C80 was 3.89 and 3.87 Å for major and minor axis respectively. The systems were 
solvated with 0.15 M of KCl, NaCl, CaCl2 solutions which count up to 24438 water 
molecules (TIP3), 20 potassium, sodium and calcium ions and 20 or 40 chloride ions in 
mono and divalent solution respectively. The CHARMM-GUI membrane [202] builder 
makes the system neutral for long-range electrostatic interactions using the particle-mesh-
Ewald method by configuring the ions position through Monte Carlo simulations 
considering the van der Waals and scaled Coulombic interactions [202].   
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Equation 1. CHARMM potential energy function. Kb, kθ, and kϕ are bond, angle and 
dihedral force constants, kω is out of plane bending force constant, Ku is Urey-Bradley 
constant, Rmin is where the Lennard-Jones potential crosses the x-axis and rij the 
distance between the interacting particles. 
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Figure 14. Molecular Assemblies of the Different Lipid Bilayers to Study the Effect of 
C80 and C80(OH)42 on the Stability of the Lipid Bilayer Structures Immersed in 
Physiological Salt Solutions. A) C80/C80(OH)42 free lipid bilayer in KCl solution, B) C80 
containing lipid bilayer in KCl solution, C) C80 containing lipid bilayer in NaCl solution, 
D) C80 containing lipid bilayer in CaCl2 solution, E) C80(OH)42 containing lipid bilayer in 
KCl solution and F) lipid bilayer containing all POPC, DSPE, Cholestrol and water 
shown to represent the whole lipid-water systems. The spheres represent K ions (white), 
sodium ions (yellow), cacium ions (purple) and the rest are chloride ions.  
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IV.3.2  MD simulations  
The simulations were run with CHARMM force field using NAMD, a parallel 
molecular dynamics code designed for high-performance simulation of large 
biomolecular systems compatible with CHARMM potential functions, parameters, and 
file formats [203]. The systems were subjected to 5,000 energy minimization steps 
followed by simulations under constant number, volume and temperature (NVT) at 1 fs 
time step up to a total of 2 ns simulations till the lipid bilayer systems were equilibrated 
(Figure 15). The production simulation was conducted at a maximum of 2 fs time step 
totaling up to 20 ns for most of the LBLs and up to 34 ns for the LBL immersed in CaCl2 
solution. Trajectory data were collected every 500 fs during equilibration and 2,000 fs 
during production stages. In all simulations, the temperature was set to physiological 
temperature (310 K) and trajectory snapshots were taken at different time frames [204]. 
All simulations in the production stage were run under constant number of atoms, 
constant pressure (1 bar) and constant temperature (i.e NPT ensemble). Langevin 
dynamics was applied to non-hydrogen atoms to maintain a 310 K constant temperature 
with a Langevin coupling coefficient of 1 ps−1. Similarly, Nosé-Hoover Langevin-piston 
algorithm was used to maintain constant pressure with a piston period of 50 fs and a 
piston decay of 25 fs [205]. The van der Waals interactions were switched off between 10 
and 12 Å by using the forced-based switching function imbedded in NAMD. The 
structural properties of fullerene-free lipid bilayer immersed in 0.15 M KCl, non-
functionalized fullerene containing lipid bi-layer in 0.15 M of KCl, NaCl and CaCl2, and 
C80(OH)42 in 0.15 M KCl were calculated during the simulations. Visual Molecular 
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Dynamics (VMD) [206] was used to create snapshots of the lipid bilayers at different 
time frames and to capture the dynamics of functionalized and non-functionalized C80 
within the lipid bilayers. Finally the evaluation parameters are plotted using QT-grace 
[207].  
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Figure 15. Equilibriation and Energy Minimization of the Different Lipid Bilayer 
Systems. The systems were equilibrated first under NVT and then under NPT before 
starting the production protocol. A) constant temperature (310 K), B) constant pressure 
(average 1 bar) and C) energy minimizations in Kcal/mol. Black lines are C80/C80(OH)42 
free lipid bilayers immersed in KCl solution, C80 containing lipid bilayers in KCl solution 
(green), C80 containing lipid bilayer in NaCl solution (yellow), C80(OH)42 containing lipid 
bilayer in KCl solution (blue) and the red lines represent C80 containing lipid bilayers 
immersed in CaCl2 solution. 
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IV.3.3  Equilibration and structural stability study 
The RMSD of C80 & C80(OH)42 were calculated using the RMSD visualizer tool 
plugin in VMD [206]. APL of each lipid species and SCDs along the carbons in Sn-1 and 
Sn-2 were computed using VMD’s MEMBPLUGIN [208]. ND profiles of water, POPC, 
DSPE, CHOL, K+, Na+, Ca++ and Cl- were computed at different time frames along the 
bilayer normal to assess bilayer structural change or ions percolation [209]. The RDF of 
K+, Na+, Ca++ and Cl- around the phosphatidyl and choline groups were determined using 
VMD [210] to assess the effect of C80 and C80(OH)42 on the distribution of bulk ions with 
respect to the lipid head groups [210]. The trajectories within 20 ns simulation are 
considered for the stability assessments. 
IV.3.4  Steered molecular dynamic simulations 
The SMD simulations are conducted at 310 K by controlling the temperature 
fluctuations using Langevin dynamics scheme embedded in NAMD with integrator 
parameter time step set to 2 femtosecond. One of the phosphorus (P) atoms of POPC was 
constrained to stationary and a carbon atom of C80/C80(OH)42 was constrained to a point 
that moves along the z-axis at a constant speed of 0.0001 Å/timestep. The center of mass 
of C80/C80(OH)42 was displaced up to a total of 80 Å by applying a harmonic potential 
having a force constant of 7.2 kcal/mole/Å. As the pulling simulation is performed very 
slowly (0.0001 Å/timestep), the process is assumed to be reversible. In other words, the 
work done during this reversible pulling process is assumed to be equal to the free energy 
difference of the system when C80/C80(OH)42 are at the origin and when displaced out of 
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the lipid bilayer. Hence, the energies required to displace C80 versus C80(OH)42 inside 
lipid bilayers immersed in 0.15 M of KCl was compared. Then the energy required to 
displace C80 inside the lipid bilayers solvated with NaCl and CaCl2 are discussed in terms 
of the interactions of monovalent and divalent ions with the lipid head groups and 
interpreted in terms of the overall stability of the lipid bilayers. To this end force profiles 
and work required to move the molecules, calculated at a constant velocity, are provided 
for structures taken at different time frames. For a detailed explanation on SMD, the 
reader is referred to NAMD application package [203]. 
IV.4 Results and Discussion 
 
To model the energy variations of Gd containing fullerenes with respect to Gd free 
counterparts, the minimization energies of the different molecules were computed using 
Tripos force field and are given in Table 6. In those quantities, two differences are clear. 
First, new electrostatic energy forms have been developed from the functionalization 
process. Second, Gd containing C80 have relatively higher bending energy compared to 
Gd free equivalents. The increment in bending energy is due to the addition of Gd3N 
atoms and it increased the stability of the molecules.  
Studying the dynamics of Gd3N@C80 and Gd3N@C80(OH)42 inside lipid bilayers by 
using any force field including CHARMM requires robust force field parameters 
encompassing the interaction of Gd, bonded and non-bonded interactions, with 
surrounding carbon and nitrogen atoms. As these parameters are typically obtained either 
from ab-initio or semi-empirical quantum mechanical calculations or by fitting to 
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experimental data such as neutron, X-ray and electron diffraction, NMR, infrared, Raman 
and neutron spectroscopy [211], the strategy was to study the interaction between the 
LBL lipid components and the fullerene cages or vice versa. Two reasons are taken in to 
account for this assumption. First, experimental evidences support the firm confinement 
and stability of Gd inside a very stable fullerene cage. Thus, the dynamics of 
Gd3N@C80/Gd3N@C80(OH)42 inside the lipid bilayers or liposomes is mainly influenced 
by the outer cage. Second, conducting molecular dynamic simulations with poorly known 
CHARMM parameters that represent the interaction of Gd with neighboring atoms, 
would result in erroneous results. Hence the structural stability discussions given below 
focus on C80 and C80(OH)42 containing lipid bilayers. To sum up as the Gd3N is common 
between in Gd3N@C80 and Gd3N@C80(OH)42 and the main structural difference is the 
OH functionalization, the stability studies herein focus on the effects of the outer 
compartments of the molecules. 
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Table 6. Energy Minimization/Geometry Optimization for Gd Containing and Gd-free C80 
& C80(OH)42 Molecules that are indicated in Figure 14. 
Energy_Type 
(Kcal/mol) 
Gd3NC80 C80 Gd3NC80(OH)42  C80(OH)42  
Bond Stretching  51.260 11.067 92.327 15.365 
Angle Bending  617.645 118.495 563.013 148.685 
Torsional  177.125 176.622 164.111 105.321 
Out of Plane Bending  1524.976 1475.513 111.380 44.313 
1-4 van der Waals  12.469 23.905 40.835 1.936 
van der Waals  236.112 -34.265 149.033 -56.897 
1-4 Electrostatic  0 0 279.909 -49.006 
Electrostatic 0 0 -782.345 35.394 
Total Energy  2619.587 1771.33 618.262  245.111 
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Table 7. Lipid Bilayers Structural Constituents of the Different Systems Indicated in 
Figure 14. Fullerene type, Solution used for Solvation, Number of Lipid Residues, ions 
and water Molecules in each Bilayer System. 
 
 
 
 
IV.4.1 Equilibration and structural studies 
IV.4.1.1 Root means square deviations (RMSD) 
RMSD provides valuable information about two structures where the value is zero 
for identical structures, and increases as the two structures become more different [212]. 
As it is shown in Figure 16, the average RMSD for C80 and C80(OH)42 is 0.075 and 0.1 Å 
respectively and the average value remain almost constant throughout the simulation 
window. These, constant close to zero values from the beginning to the end of 20 ns 
simulation window, indicate that C80 as well as C80(OH)42 remain structurally stable 
within the lipid bilayers throughout the simulation time. The relatively larger RMSD 
(~0.025 Å) observed in the functionalized structure compared to the non-functionalized 
 C80(OH)42 
LBL 
C80 
LBL 
C80 
LBL 
C80 
LBL 
no C80 and 
derivative 
Sol. KCl KCl NaCl CaCl2 KCl 
POPC 36448 36448 36448 36448 36448 
DSPE 2128 2128 2128 2128 2128 
CHOL 2368 2368 2368 2368 2368 
Water 24438 24465 24420 24432 35007 
Cation 20 20 20 20 30 
Anion 20 20 40 20 30 
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counterpart could be due to OH functional groups which caused C80(OH)42 to have a 
relatively larger size and to show a relative structural change probably due to OH induced 
oscillations. 
 
 
Figure 16. Avergae RMSD Plots of C80 and C80(OH)42 inside the LBLs. A) RMSD in the 
first 2000 time frames and (B) RMSD of the last 200 frames of the 20 ns simulation. The 
green line represents RMSD of C80 inside of a lipid bilayer immersed in KCl solution, 
RMSD of C80(OH)42 inside a lipid bilayer immersed in KCl solution is shown in blue, 
yellow line reperesent RMSD of C80 placed in a lipid bilayer that was immersed in NaCl 
solution and red line RMSD of C80 indie of lipid bilayer in CaCl2 solution. 
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IV.4.1.2 Area per lipid (APL) and average thickness 
APL is a crucial parameter which reflects lipid membrane properties, such as acyl 
chain ordering, compressibility, and molecular packaging. The time dependence of APL 
is also a good criterion to determine if a system has reached a steady state [213]. As 
shown in Figure 17 A, the APL for C80\C80(OH)42-free and C80(OH)42 loaded lipid 
bilayers were similar from the beginning till the 20 ns simulations with a difference of 
about ~1.6%. This implies that, the presence of C80(OH)42 doesn’t have any effect on the 
APL of POPC in the lipid bilayer. The APL of POPC in C80-loaded lipid bilayer appears 
lower at the beginning but reaches to a 1.6% difference at later times in the simulation. 
The APL of DSPE is lower for C80 containing lipid bilayer immersed in KCl solution 
compared to C80 free and C80(OH)42 containing lipid bilayers in KCl solution for 
simulations conducted below 2 ns (Figure 17 B). These differences however become 
lower at later time of the simulation (Figure 17 B) which signifies the reorganization of 
the lipids to maintain the bilayer structure. Those observations are in accordance to the 
average thickness reported for the lipid bilayers (Figure 17 C) where the difference 
between C80(OH)42 containing and C80(OH)42-free bilayers was almost negligible 
throughout the simulation window. Comparing the APL of POPC in C80 loaded lipid 
bilayer immersed in monovalent versus divalent salt solutions indicate slight difference at 
the beginning of the simulation which may suggest lipid swelling in the latter. The APL 
difference between C80 containing bilayer in KCl solution and those immersed in NaCl 
and CaCl2 was ~6%, observed within the first 2 ns, and this could be the cause for 
corresponding thickening of the bilayer resulting from the swelling of the lipids and these 
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results may signal a reorganization of the lipid bilayer at those simulation windows. 
While the difference in average thickness between C80(OH)42 containing and 
C80/C80(OH)42 free LBLs is low (Figure 17 C), there was about 4 Å difference between 
C80 containing LBLs immersed in in NaCl and CaCl2 solution from the C80/C80(OH)42-
free counterparts at the beginning of the simulation. These differences however, 
decreased as at a later time in the simulation (Figure 17 C). 
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Figure 17. The Effect of C80/C80(OH)42 on APL of POPC, DSPE and on the Lateral 
Average Lipid Bilayer Thickness (LBT) throughout the Simulation. A) APL of POPC 
where, the first 2000 frames are shown at the top and the last 2000 frames of the 20 ns 
simulation at the bottom. B) APL of DSPE where, the first 2000 frames are shown at the 
top and the last 200 frames of the 20 ns simulation at the bottom. C) Lateral average 
thickness of the LBLs.in the first 2000 and the last 2000 frames. Black, green, yellow, red 
and blue lines are designated for C80/C80(OH)42 free lipid bilayer immersed in KCl 
solution, C80 containing lipid bilayer in KCl solution, C80 containing lipid bilayer in NaCl 
solution, C80 containing lipid bilayer in CaCl2 solution and C80(OH)42 containing lipid 
bilayer in KCl solution respectively.  
A 
B 
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IV.4.1.3 Order parameter (SCD) 
C80 as well as C80(OH)42 did not affect the overall carbon-deuterium order of Sn-1 
& Sn-2 chains as depicted by insignificant SCDs difference between C80/C80(OH)42-free 
LBL and C80/C80(OH)42 containing LBLs (Figure 18). In general, the SCD values are 
higher close to the glycerol group and decreases towards the end of the tails (Figure 18). 
These values imply that the acyl chains of POPC and DSPE have a higher ordered in the 
head groups with a relatively less order towards the tail. These order parameter values are 
in agreement to those reported in [214]. 
The SCD of POPC in lipid bilayers depends on the percentage of CHOL 
incorporated into the LBLs [215]. In general, order parameter values in the Sn-1 and Sn-2 
chains of POPC increase with the percentage of CHOL. For instance, a zero to 34 % 
incorporation of CHOL in a POPC + CHOL mixed bilayer was reported to increase the 
order parameter in the Sn-2 chain [215]. Therefore, a 1 to 1 comparison of the SCDs of 
POPC in lipid bilayers having different percentage of CHOL could mislead. However, as 
shown in Figure 18, SCD increase towards the head group, in both chains, and these 
values are in line to those reported in [215, 216]. Less symmetric SCD of DSPE 
compared to that of POPC could be due to the difference in phase transition between the 
two lipids where DSPE requiring a relatively higher temp (> 310 K). As the percentage of 
DSPE in the lipid bilayer structures is 5%, and as they are distributed throughout the 
membrane, the overall effect of DSPE could be insignificant. Considering the whole 
system, the SCD of the lipid bilayers containing C80 or C80(OH)42 is not different from the 
SCD of C80-free lipid bilayer immersed in the same salt solution. Furthermore, the SCD 
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of C80 containing lipid bilayer is similar in different salt solutions. However, the SCDs of 
POPC located at < 40 Å, < 20 Å, <10 Å and < 5 Å from C80 indicated an intriguing 
result. The SCDs decrease as the lipids get closer to C80 (Figure 19). The local SCD 
decrement however is not significant enough to disturb the whole lipid bilayer system. 
On the other hand, lipids residing closer to C80(OH)42 never shown SCD variation as in 
the case of those residing closer to C80. These results may imply that OH 
functionalization of C80 may have a positive effect in keeping the phase property of 
POPC. 
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Figure 18. Simulated SCDs of POPC and DSPE to Study the Effect of C80/C80(OH)42 on 
the Structural Stability of the Lipid Bilayers. Figure (A) SCDs along the Sn-1 chain and 
(B) SCD along Sn-2 chain. In each panel the SCD of POPC is shown on the left column 
and the SCD of DSPE is shown on the right. The top panels in each figure represent 
SCDs of the lipids at the beginning of the simulation and the bottom panels represent the 
SCDs after 20 ns simulation.  
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Figure 19. Simulated Carbon Deuterium SCD of POPC in the Presence of 10% of CHOL 
and 5% DSPE to Study the Effect of C80/C80(OH)42 on Local Lipids. The panels represent 
(A) SCD along the Sn-1 chain and (B) Sn-2 chain. SCDs labeled in circle represent SCD 
of the whole system, SCD of lipids within 40 Å from C80/C80(OH)42 (square), < 20 Å 
(diamond), < 10 Å (upward triangle) and < 5 Å (inverted triangle). The SCD simulations 
are conducted taking the last 50 frames of the 20 ns simulation. 
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IV.4.1.4 Number density profiles (NDP) 
To assess the effect of local lipid SCD change on the overall stability of the 
system, the next strategy was to study water percolations, ion displacements and the 
localization of lipids. For this purpose, the number density of water, ions and lids is 
investigated (Figure 20). The width of a zero water number density region is in accord to 
the average thickness reported in Figure 17 and the lipid bilayers were stable enough to 
preclude water from entering as shown in the NDPs simulated in the beginning and at the 
end of 20 ns simulations. Similarly, the ions remain outside of the lipid bilayer 
throughout the simulation period for C80/C80(OH)42 loaded as well as C80/C80(OH)42 free 
lipid bilayers (Figure 20). In other words, no cations as well as anions were observed 
within the lipid bilayer (-20 to 20 Å vertical distance) throughout the simulation time 
windows (Figure 20). This indicates that, loading the membranes with C80/C80(OH)42 
doesn’t affect lipids arrangement as well as it doesn’t cause the ions/water to percolate 
deep into the lipid bilayer through the SCD compromised lipids situated closer to the 
molecules (Figure 20, Figure 21). From these ion distribution profiles, it is also evident 
that calcium, potassium and sodium ions seem to be strongly bound to the water side 
shown by a higher ions density closer to the lipid head group compared to the distribution 
in the hydrophobic region (Figure 20). These observations accord the information 
conveyed by POPC, DSPE and CHOL number density profiles indicated in Figure 21. In 
the region where the water density is zero, POPC, DSPE and CHOL number density is 
high and vice versa. These observations are similar for C80/C80(OH)42 loaded and 
C80/C80(OH)42 free lipid bilayers. Furthermore, there is no difference in water permeation, 
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ions percolation or lipid arrangement in C80 containing lipid bilayers attributed to the type 
of salt solutions used for solvation.  
 
 
Figure 20. Water and ions Number Density Profiles to Study if C80/C80(OH)42 Disrupt the 
Lipid Bilayer Structural Integrity. Or if the Interaction of Ions with the Lipid Bilayer 
Head Groups induce Percolation of ions/water into the Lipid Bilayers. A) Water (left) and 
chloride ions (right) number densities. B) Sodium & calcium ( left) and potassium (right) 
number densities. The profiles are averages of the last 200 frames of 20 ns simulations. 
Black lines/points represent C80/C80(OH)42 free lipid bilayer in KCl solution, green 
lines/points represent C80 containing lipid bilayer in KCl solution, yellow lines/points 
represent C80 containing lipid bilayer in NaCl solution, red lines/points are C80 containing 
lipid bilayer in CaCl2 solution and blue lines/points represent C80(OH)42 containing lipid 
bilayer in KCl solution. 
A 
B 
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Figure 21. NDP of POPC, DSPE and CHOL to Study the Effect of C80/C80(OH)42 on the 
Stability of the Hydrophobic Region of the LBL. The profiles are, A) POPC, B) DSPE, 
C) CHOL and D) POPC & water combined. Black, green, yellow, red and blue lines 
respectively represent C80/C80(OH)42 free LBL in KCl solution, C80 containing LBL in 
KCl solution, C80 containing LBL in NaCl solution, C80 containing LBL in CaCl2 
solution and C80(OH)42 containing LBL in KCl solution respectively. 
 
 
IV.4.2 Assessing the stability of C80/C80(OH)42 LBLs in physiological salt solutions 
IV.4.2.1 Radial distribution functions (RDF) 
RDF analysis to investigate the effect of C80/C80(OH)42 on the localization of K+, 
Na+ and Ca++ around phosphate head groups in POPC indicated a relatively higher 
cations accumulation around 3.8 Å from the phosphorus in POPC. This peak position 
remains the same for C80/C80(OH)42 free lipid bilayer as well as for those C80 and 
C80(OH)42 containing LBLs (Figure 22). These results imply that the presence of either of 
the molecules didn’t affect the interaction of POPC phosphate groups with K+, Na+ as 
A B 
C D 
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well as with Ca++. While the cations start to assemble > 4 Å from the nitrogen in the lipid 
head groups, there is no difference on the localization or on the number of K+ around 
nitrogen between C80/C80(OH)42 containing and C80/C80(OH)42-free LBLs immersed in 
the same solution (Figure 22). The Cl- are localized around 4.5 Å from nitrogen of POPC 
in all the systems. The higher RDF amplitude observed for the lipid bilayer immersed in 
CaCl2 solution could be due to the excess Cl- present in CaCl2 solution compared to the 
number of Cl- present in KCl and NaCl solutions. To sum up, the cations and anions 
distribution around phosphate and nitrogen head groups in POPC remains almost similar 
in C80/C80(OH)42 containing and C80/C80(OH)42 free lipid bilayers. 
 
 
86 
 
 
 
Figure 22. Radial Distribution Function of Cations and Anions with Respect to the Lipid 
Head Groups. The simulations are taken at the Beginning (A) and end of 20 ns 
simulations (B) to investigate the effect of C80/C80(OH)42 on ions distributions and to 
study the stability of POPC, DSPE and CHOL containing LBLs in physiological salt 
solutions. The top panels of each figure constitute the distribution of cations with respect 
to N in POPC (left) and with respect to P of POPC (right). Cl- distribution with respect to 
N of POPC (left) and with respect to P of POPC (right) are shown at the bottom. Black, 
green, yellow, red and blue lines represent the RDF of K+ in C80/C80(OH)42 free LBL 
immersed in KCl solution, K radial distribution in C80 containing LBL immersed in KCl 
solution, RDF of Na+ in C80 containing lipid bilayer in NaCl solution, Ca++ RDF in C80 
containing LBL immersed in CaCl2 solution, and K+ RDF in C80(OH)42 containing LBL 
immersed in KCl solution respectively. 
A 
B 
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IV.4.2.2 Lipid interdigitation and bilayer thickness (LI & LBT) 
In optimally stable lipid bilayer structure, the distance between the two lamellae 
(leaflets) remains constant. However, in non-stable or compromised lipid bilayer the 
structures could be disturbed and the lipids in each leaflet may cross or subject to 
interdigitation. For instance, in a ripple and fluid phases lamellae the phase transition 
induces thinning and inter-leaflet interdigitations [217]. From the leaflet overlap and 
fraction of atoms in contact shown in Figure 23, one can see that there is no much 
difference on the degree of overlap between the leaflets among C80/C80(OH)42 containing 
and C80/C80(OH)42 free lipid bilayers. It is evident, however, that the degree of leaflet 
overlap as well as fraction of atoms in contact remains more equivalent in C80(OH)42 
containing lipid bilayer and C80/C80(OH)42 -free bilayer compared to those C80 containing 
counterparts. However, in all the lipid bilayers there was no abrupt change in leaflet 
overlap that signify separation of leaflets or extreme interdigitation. These results imply 
that the lipid bilayers demonstrated stable and ordered assembly for all the simulation 
time windows considered. In other words, the C80/C80(OH)42 molecules have never 
induced lipid interdigitation as well as a perturbation that could affect the structural 
stability of the bilayers.  
A 3D thickness map of a lipid bilayer devoid of C80/C80(OH)42 indicates about 10 
Å variations (Figure 24). Thickness variations in C80/C80(OH)42 containing lipid bilayers 
are also within the same range (Figure 24, Figure 25). Relatively thicker or thinner 
patches (~4 Å thicker from average) were observed in all the lipid bilayers irrespective of 
the type of molecule loaded or the salt solutions. The relative thickenings were thought to 
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be related to the localization of CHOL as reported in [218] where CHOL had increased 
the thickness of 1,2 dimyristoleoylphosphatidylcholine (diC14:1PC) bilayers by 0.54 ± 
0.03 nm. Nevertheless, the thick layer patches in this study seem to be unrelated to the 
localization of either CHOL, DSPE or C80/C80(OH)42 (Figure 24, Figure 25). 
Furthermore, the localization of C80 seems to be unrelated to the type of solution that the 
bilayers are immersed in (Figure 26). 
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Figure 23. The Effect of C80/C80(OH)42 on Lipid Interdigitation of POPC, DSPE and 
CHOL Containing Lipid Bilayer Immersed in Different Physiological Salt Solutions. A) 
Correlation based leaflet overlap (in nm) and the fraction of LBL atoms in contact 
calculated for the first 2000 frames and (B) the last 200 frames of the 20 ns simulation. 
Black, green and blue lines represent lipid interdigation level of C80/C80(OH)42 free lipid 
bilaye, C80 containing lipid bilayer, and C80(OH) containing lipid bilayer all immersed in 
KCl solution respectively. Yellow and red lines represnet C80 conatining lipid bilayers 
immersed in NaCl solution and CaCl2 solution respectively.  
B 
A 
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IV.4.2.3 Localization and dynamics of C80/C80(OH)42 in the lipid bilayer 
Investigating the localization of C80/C80(OH)42 within the lipid bilayer is 
important for it hints the possible interactions of these molecules with different lipid 
components. It was previously reported that the preferred localization of the non-
hydrophobic C60 within DMPC lipid bilayer to be off the center [219]. As shown in 
Figure 24, the localization of C80 inside a lipid bilayer immersed in KCl solution, accords 
the reports in [219] where C80 was displaced towards the lipid head groups during the 
simulation. As in the case of C80, C80(OH)42 was also displaced towards the lipid head 
group (Figure 25). The displacement of C80(OH)42 as well as its proximity towards the 
head groups however never induced structural change on the overall bilayer structure as 
confirmed by the SCDs reported in section 3.1 and this result generally accords the 
reports in [196]. Further, the closeness of C80(OH)42 towards lipid head groups never 
induced lipid interdigitation or leaflet separation (Figure 23) and it didn’t affect the 
distribution of water and ions around the head groups (Figure 21). The absence of 
structural change due to lipid oxidation in C80 containing bilayers, contrary to previous 
report where C60 was reported to cause such effect, could be either due to the chain 
differences between DMPC and POPC or could be due to the presence of different lipids 
in this study. CHOL might have increased the order of POPC which in turn help resist 
any structural change that C80 would have instigated. Furthermore, there is no 
considerable difference on the localization of the molecules resulting from the type of salt 
solution in which the bilayers are immersed (Figure 26).  
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Figure 24. The Localization of C80 inside Lipid Bilayer Immersed in KCl Solution after 
20 ns Simulation Window. A lipid bilayer free of C80 is shown on the left column and on 
the right C80 containing lipid bilayer. The figures from top to bottom represent, the 
localization of C80 off the center closer to lipid head group, localization of CHOL and the 
localization of DSPE inside the lipid bilayer respectively. The lipid bilayers are drawn on 
black-white-red (BWR) color scale to investigate if lateral bilayer thickness relates to the 
localization of C80, CHOL or DSPE. From the figures it is evident that C80 never induced 
thickening or thinning of the lipid bilayer in 0.15 M KCl solution.  
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Figure 25. The Localization of C80(OH)42 inside Lipid Bilayer Immersed in KCl Solution 
after 20 ns Simulation Window. A lipid bilayer free of C80(OH)42 is shown on the left 
column and on the right C80(OH)42 containing lipid bilayer. The figures from top to 
bottom represent, the localization of C80(OH)42 off the center closer to lipid head group, 
localization of CHOL and the localization of DSPE inside the lipid bilayer respectively. 
The lipid bilayers are drawn on BWR to investigate if lateral bilayer thickness change 
relates to the localization of C80(OH)42, CHOL or DSPE. From the figures it is evident 
that C80(OH)42 never induced thickening or thinning of the lipid bilayer in 0.15 M KCl 
solution.  
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Figure 26. Comparison of the Localization of C80 inside Lipid Bilayer Immersed in KCl 
and CaCl2 Solutions after 20 ns Simulation Window. A lipid bilayer containing C80 in 
KCl solution is shown on the left column and on the right, C80 containing lipid bilayer in 
CaCl2 solution. The figures from top to bottom represent, the localization of C80 off the 
center closer to lipid head group, localization of DSPE and the localization of CHOL 
inside the lipid bilayers respectively. The lipid bilayers are drawn on BWR color scale to 
indicate if a change in bilayer thickness is related to the localization of C80. As in the case 
of KCl Solution, it is evident that C80 never induced thickening or thinning of the lipid 
bilayer solvated in 0.15 M CaCl2 solution. However, the thinning on the lipid bilayer in 
CaCl2 compared to the on in KCl solution could be attributed to Ca++.  
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IV.4.3 Steered Molecular Dynamic Simulation (SMD) 
The purpose of the SMD was to compare the amount of forces needed to displace 
C80 versus C80(OH)42 across the different regions of the lipid bilayers and then understand 
the stability of the particles inside the LBLs through energy computations. The 
displacements of the particles in non-restrained simulation are portrayed in Figure 27 & 
Figure 28 and corresponding displacement trajectory videos are provided as 
supplementary materials. The energy computations revealed that more energy was 
required to drive C80(OH)42 out of the LBL structure compared to the amount of energy 
required to displace C80 out (Figure 29). As the steered molecular dynamic simulations 
were conducted at a very low velocity (0.0001 Å/timestep), the process is considered 
reversible. Therefore, the total energy required to displace the molecules along a 
complete LBL trajectory is twice of the energy required for half of the course. 
Furthermore, the energy required to move a molecule at two trajectories taken 1250 
frames apart look identical (Figure 29).  
To study the combined effect of ions and lipids on the dynamics of C80, the 
dynamics of C80 inside LBLs immersed in KCl, NaCl and CaCl2 solutions is explored 
(Figure 29, Figure 30). The relatively higher energy required to move C80 inside LBL in 
NaCl solution compared to the energy required to displace it inside the LBL in KCl 
solution could be due to a stronger localization or interaction of Na+ with phosphorus or 
other atoms in POPC compared to the localization and interaction of K+ around the same 
atoms (Figure 22 lower panel). A firm interaction between Na+ and POPC might have 
helped a higher order lipid arrangement resulting in a stronger contact/friction between 
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C80 and POPC. This is also supported with the change in SCD of the lipids residing closer 
to C80 which was more pronounced in the LBL immersed in KCl solution compared to 
the LBL in NaCl solution (Figure 19). Similarly, higher energy was required to move C80 
within the lipid bilayer immersed in the CaCl2 solution (Figure 30). To sum up, the 
differences in the amount of energy required to displace C80 inside of LBLs immersed in 
different salt solutions could be mainly due to the interactions between the ions and 
POPC. 
Although the major causes for the higher energy requirement to move C80(OH)42 
inside the lipid bilayer is uncertain, hydroxyl functionalization, differences in 
electrostatic energy of the molecules, and SCD differences of the lipids residing closer to 
the molecules could be some of the factors. To assess the OH functionalization effect, the 
amount of energy required to move the two molecules in the bulk solution was evaluated 
(Figure 30). This computation revealed that more energy is needed to displace C80(OH)42 
inside the bulk solution which most likely is due to a hydrogen bonding between the OH 
in functionalized C80 and surrounding water molecules. To assess if similar phenomenon 
contributed for the higher energy requirement to displace C80(OH)42 inside the lipid 
bilayer, hydrogen bonds formed between C80(OH)42 and POPC are evaluated using 
VMD’s HBonds plugin [206] by setting a 3 Å donor-acceptor distance and 20 degrees’ 
angle cut-off. As shown in Figure 30, new hydrogen bonds start to immerge after 1-3 nm 
simulation windows. Hence, the energy required to move C80(OH)42 needs to have 
additional energy to break the new hydrogen bonding in addition to the energy required 
to move C80. This is also supported by the shifting in the magnitude of the energy 
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required to move C80(OH)42 inside KCl bulk solution compared to the energy required to 
move C80 (Figure 30). The energy required to move C80 in KCl and CaCl2 solutions 
became almost constant, Figure 30, while the energy required to move C80(OH)42 
increases inside the bulk solution due to hydrogen bonding of the later with water.  
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Figure 27. Steered Molecular Dynamic Simulationto to Study the Dynamics of C80 Inside 
of a Lipid Bilayer Immersed in KCl Solution. The trajectories are taken at different time 
frames to indicate C80 crossing different regions of the lipid bilayer. Beginning of the 
trajectory indicated on the top-left and the molecule emerging out of the lipid bilayer 
shown on the bottom-right. Blue, green and red points represent phosphorus, nitrogen and 
oxygen atoms constituting the lipid bilayer.  
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Figure 28. Steered Moleculard Dynamic Simulation to Study the Dynamics of C80(OH)42 
Inside a Lipid Bilayer Immersed in KCl Solution. The tajectories are taken at different 
time frames to indicate C80(OH)42 crossing different regions of the lipid bilayer. 
Beginning of the tajectory is indicated on the top-left and the molecule emerging out of 
the lipid bilayer on the bottom-right. Blue, gren and red points represent P, N and oxygen 
atoms constituting the lipid bilayer. The functionalization of C80 with OH is shown using 
red/white points portraying hydrogen & oxygen atoms attached to C80.   
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Figure 29. Applied Force Profiles for the Trajectories of C80 and C80(OH)42 to Cross the 
Different Regions of the Lipid Bilayers and the Energy Required to Move the Molecules 
along the Trajectory at 750 (top) & 2000 (bottom) Time Frames. In the top panel, green 
profiles represent forces applied to move C80 inside LBL immersed in KCl solution, the 
yellow profiles represent applied force to move C80 inside LBL immersed in NaCl 
solution and blue profiles represent the force to move C80(OH)42 inside LBL immersed in 
KCl solution. Same color representations are used to indicate the energy required to move 
C80 & C80(OH)42 across LBL immersed in KCl, NaCl and CaCl2 solutions (bottom panel).  
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Figure 30. Steered Molecular Dynamics Simulation of C80 & C80(OH)42 Inside of Lipid 
Bilayers Solvated using Physiological Salt Solutions. The panels are applied force versus 
displacement (Kcal/mol/A) shown on the top, energy required to displace C80 & 
C80(OH)42 across the different regions of the lipid bilayers (middle) & the number of new 
hydrogen bonds developed between C80(OH)42 & POPC (bottom). Green, red and blue 
lines represent C80 containing LBL in KCl solution, C80 containing LBL inCaCl2 solution 
and C80(OH)42 containing LBL in KCl solution respectively. The more work required to 
displace C80(OH)42 over C80 across the lipid bilayers are associated to the new hydrogen 
bonds developed between C80(OH)42 and POPC at later time in the simulations. 
Furthermore, the work required to displace C80 in a lipid bilayer immersed in divalent 
solution (CaCl2 solution) is higher than displacing it inside a lipid bilayer immersed in 
monovalent solution (KCl solution).  
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IV.5 Conclusions  
 
Gd-fullerene is a widely researched MRI contrast agent, but the details of its 
dynamics in liposomal lipid bilayers remain poorly understood. This chapter investigated 
the structural stability of C80/C80(OH)42 containing lipid bilayers immersed in different 
physiological salt solutions. The structural stability of C80/C80(OH)42 containing lipid 
bilayers immersed in different physiological salt solutions was investigated and the 
results indicated that while lipids residing closer (< 20 Å) to C80 were shown to have a 
decreased SCD, those residing closer to C80(OH)42 remain stable. The local SCD change 
in, C80 loaded bilayers, however didn’t affect the overall stability of the bilayers. Density 
profiles of water, K+, Na+, Ca++, Cl-, POPC, DSPE and CHOL at different simulation 
windows indicated that C80 as well as C80(OH)42 did not affect the structural stability of 
the lipid bilayers for simulations conducted up to 20 ns as supported by water 
impermeability or similarity in the localization of cations, anions or lipids. These 
observations are also in line with lipid interdigitation analysis where no significant 
differences are observed in leaflet overlap or lipid interdigitation between C80/C80(OH)42 
containing and C80/C80(OH)42 free LBLs throughout the simulation. The SMD 
computations revealed that a higher energy is required to displace C80(OH)42 across 
POPC, CHOL and DSPE containing LBL in KCl solution compared to the energy 
required to displace C80 across the same trajectory. Tow possible reasons may attribute to 
the higher energy need to displace C80(OH)42 compared to C80. First, it could be due to 
the higher SCD of lipids residing closer to C80(OH)42 compared to those residing closer to 
C80. Second, C80(OH)42 was able to form hydrogen bonding with POPC which might 
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have increased the stability of the molecule within the bilayer. The conclusion of these 
analyses is that POPC, DSPE, CHOL, C80(OH)42 assembly is much more stable in 
physiological solutions compared to POPC, DSPE, CHOL, C80 assembly. Furthermore, 
C80/C80(OH)42 never induced structural instability in these LBL formulations. These 
results also imply that Gd3N@C80(OH)42 containing liposomes to be stable in 
physiological environment compared to Gd3N@C80 containing liposomes. 
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CHAPTER V 
 
DISSERTATION SUMMARY 
 
 
The thesis had three specific objectives. First, studying the state of the art of 
theranostic liposomes and identify potential targets for theranostic delivery. Second, to 
develop novel glioblastoma theranostic liposome with higher imaging and cancer cells 
killing capability. Third, study the structural stability of these experimentally developed 
theranostics in physiological salt solutions and at body temperature by using molecular 
dynamics simulations.  
In the first chapter the state of the art of theranostics liposomes are discussed, 
categorically, in detail with more emphasis on formulation mechanisms, challenges and 
possible improvement directions for their usage in glioma treatments. This updated 
review is different from the previous reviews in that it focuses only on liposomes and 
hence have a better coverage on theranostic liposomes. Targets that are often used for 
drug delivery are presented but also new potential glioma biomarkers mined from 
different databases and the literature are discussed with more emphasis on their role in 
gliomas migration, proliferation, activation etc. The novelty of the targets identification 
process is that patient databases such as TCGA, the protein atlas and REMBERANDT 
are accessed and the application of the identified targets are reviewed in the literature. 
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These new biomarkers can be targeted to improve the delivery of imaging agents and 
cytotoxic or cytostatic drugs through ligand-receptor mediated endocytosis, antibody 
(fragment) based delivery, peptide based delivery, or other mechanisms such as a 
recombinant immunotherapy modality. 
In the second chapter the design and testing of a dual-targeted theranostic is 
discussed in detail. For the first time Gd3N@C80(OH) and DXR encapsulated theranostic 
liposome conjugated with transferrin (Tf) and lactoferrin (Lf) is developed and tested. 
The novelty of this formulation is that besides to having the novel higher contrast agent 
Gd3N@C80(OH), it has a potential to cross the BBB through lactoferrin receptors, 
transferrin receptors or both depending on the expression level of the receptors and 
targets transferrin or lactoferrin receptors expressing cancer cells. To this end, the 
hydrodynamic size, zeta potential, encapsulation efficiency and the assembly of 
Gd3N@C80(OH) and DXR loaded liposomes are characterized. The functionalization, 
tagging and PEGylating of the liposomes are also verified using Fourier-transform 
infrared spectroscopy (FTIR) and ultraviolet-visible spectrophotometry (UV-VIS) 
analysis. Cell viability test on U251-MG cells indicated successful delivery of DXR via 
Tf and dual (Tf & Lf) tagged theranostics. Importantly, the dual targeted liposomes were 
able to significantly induce cell death compared to cells death recorded for lactoferrin, a 
less expressed receptor on U251-MG cell, targeted liposomes. Furthermore, drug-free 
liposomes treated cells never shown a significant viability difference from untreated cells 
indicating the biocompatibility of the lipid components of the liposomes. 
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In the third chapter the dynamics and structural stability of Gd-fullerene 
(Gd3N@C80) inside of lipid bilayers immersed in physiological salt solutions and the 
interactions of those molecules with the lipid bilayer constituents are discussed in detail. 
The novelty is that for the first time the structural stability of C80/C80(OH)42 containing 
POPC: DSPE: Cholesterol lipid bilayers that are immersed in 0.15 M KCl, NaCl and 
CaCl2 are evaluated using, NAMD, molecular dynamic simulations. The stability study is 
realized by computing root means square deviations, area per lipid, radial distribution 
functions of ions, number density profiles, order parameters, lipid bilayer thickness and 
lipid interdigitations and these results are discussed in terms of the effect of the molecules 
on the lipid bilayer structures or vice versa. Furthermore, the dynamics of the fullerene 
cages, i.e. C80/C80(OH)42, across different regions of the lipid bilayers are studied using 
steered molecular dynamics simulations. The results indicate that C80/C80(OH)42 remains 
structurally stable throughout the simulation windows. The energy required to displace 
C80(OH)42 across the lipid bilayer is found to be higher than the energy required to 
displace C80, partly, due to hydrogen bonding of the former with the head groups of 
POPC. Further, a lower SCD of the lipids closer to C80 compared to the lipids residing 
closer to C80(OH)42 might have contributed for the less stability of C80 containing LBLs 
compared to those loaded with C80(OH)42. These results, along with experimental and 
computational studies which proven the stability of Gd3N inside C80 support the 
hypothesis that OH-functionalized fullerene cages and thereby OH functionalized Gd-
fullerene containing liposomes to be stable in physiological salt solutions and are in 
accordance with the experimental observations reported in the second chapter. 
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APPENDIX A  
 
SUPPLEMENTARY FIGURES 
 
 
 
 
Supplementary Figure 31. Localization of C80 Inside Lipid Bilayer Immersed in KCl 
Solution after 10 ns Simulation Window (similar to Figure 24 but 10 ns earlier). A lipid 
bilayer free of C80 is shown on the left column and on the right C80 containing lipid 
bilayer. The figures from top to bottom represent, the localization of C80 off the center 
closer to lipid head group, localization of CHOL and the localization of DSPE inside the 
lipid bilayer respectively. The lipid bilayers are drawn on BWR color scale (35-45 Å 
thickness) to indicate if lateral bilayer thickness relates to the localization of C80, 
Cholesterol or DSPE. From the figures it is evident that C80 never induced thickening or 
thinning of the lipid bilayer in 0.15 M KCl solution. 
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Supplementary Figure 32. Localization of C80(OH)42 Inside Lipid Bilayer Immersed in 
KCl Solution after 10 ns Simulation Window (similar to Figure 25 but 10 ns earlier). A 
lipid bilayer free of C80(OH)42 is shown on the left column and on the right C80(OH)42 
containing lipid bilayer. The figures from top to bottom represent, the localization of 
C80(OH)42 off the center closer to lipid head group, localization of CHOL and the 
localization of DSPE inside the lipid bilayer respectively. The lipid bilayers are drawn on 
BWR color scale (35-45 Å thickness) to indicate if lateral bilayer thickness change 
relates to the localization of C80(OH)42, cholesterol or DSPE. From the figures it is 
evident that C80 never induced thickening or thinning of the lipid bilayer in 0.15 M KCl 
solution. 
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Supplementary Figure 33. Comparison of the Localization of C80 Inside Lipid Bilayer 
Immersed in KCl and CaCl2 Solutions after 10 ns Simulation (similar to Figure 26 but 10 
ns earlier). A lipid bilayer containing C80 in KCl solution is shown on the left column and 
C80 containing lipid bilayer in CaCl2 solution on the right. The figures from top to bottom 
represent, the localization of C80 off the center closer to lipid head group, localization of 
CHOL and the localization of DSPE inside the lipid bilayer respectively. The lipid 
bilayers are drawn on BWR color scale (35-45 Å thickness) to indicate if a change in 
bilayer thickness relates to the localization of C80. From the figures it is evident that C80 
never induced thickening or thinning of the lipid bilayer solvated with 0.15 M CaCl2 
solution. However, the thickening on the lipid bilayer in CaCl2 compared to the on in KCl 
solution could be attributed to the Ca++. 
 
 
 
 
 
 
128 
 
APPENDIX B  
 
SUPPLEMENTARY FILES 
 
 
Supplementary information 1. The file contains supplementary movie which indicates the 
Brownian motion of liposomes captured using Nanosight Nano tracking analysis. The file 
is associated to Figure 5. 
 
Supplementary information 2. The file contains supplementary movie which indicates the 
dynamics of C80 inside POPC: DSPE: Cholesterol lipid bilayer immersed in KCl solution. 
The file is associated to Figure 24. 
 
Supplementary information 3. The file contains supplementary movie which indicates the 
dynamics of C80(OH)42 inside POPC: DSPE: Cholesterol lipid bilayer immersed in KCl 
solution. The file is associated to Figure 25. 
 
Supplementary information 4. The file contains supplementary movie to indicate the 
dynamics of C80 inside POPC: DSPE: Cholesterol lipid bilayer immersed in CaCl2 solution. 
The file is associated to Figure 26. 
 
Supplementary information 5. The file contains supplementary movie to indicate steered 
molecular dynamics simulation of C80 inside POPC: DSPE: Cholesterol lipid bilayer 
immersed in NaCl solution. The file is associate to Figure 27. 
 
Supplementary information 6. The file contains supplementary movie to indicate steered 
molecular dynamics simulation of C80 inside POPC: DSPE: Cholesterol lipid bilayer 
immersed in CaCl2 solution. The file is associated to Figure 28. 
 
Supplementary information 7. The file contains supplementary movie to indicate steered 
molecular dynamics simulation of C80 inside POPC: DSPE: Cholesterol lipid bilayer 
immersed in KCl solution. The file is associated to Figure 30. 
 
Supplementary information 8. The file contains supplementary movie to indicate steered 
molecular dynamics simulation of C80(OH)42 inside POPC: DSPE: Cholesterol lipid bilayer 
immersed in KCl solution. The file is associated to Figure 30. 
 
 
 
 
 
